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Abstract 
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an inflammatory 
autoimmune peripheral nerve disorder. CIDP is associated with demyelination, slow 
motor nerve-conduction velocity, and distal muscle weakness. CIDP is under-recognized 
due to its heterogeneous presentation and the limitations of clinical diagnostic criteria. 
Using a combination of electrophysiology and muscle imaging techniques the four 
studies outlined in this thesis systemically investigate the impacts of this demyelinating 
disease on motor nerves and their innervated muscles.  
The first two studies examine the neuronal consequences of demyelination caused by 
CIDP and the following two studies investigate how skeletal muscle is affected by these 
neuronal complications. Specifically, the purpose of study 1 was to investigate whether 
patients with CIDP demonstrate motor unit loss, and to determine the neuromuscular 
transmission stability of motor units.  Results showed patients with CIDP have reduced 
motor unit number estimates (MUNEs), in addition to motor unit instability and 
transmission blocking in the tibialis anterior (TA) muscle. The purpose of study 2 was to 
investigate modifications to motor unit discharge characteristics of affected motor units. 
The results indicate CIDP leads to axonal or neuromuscular block and abnormally high 
motor unit firing rates of early recruited motor units as a compensatory mechanism to 
mitigate the frank neuronal loss in the TA.  
The purpose of studies 3 and 4 was to assess the consequences of peripheral axon loss 
and motor unit instability on muscle quality and quantity in patients with CIDP. It is 




musculature. Study 3 showed that patients with CIDP have less overall muscle mass and 
more non-contractile tissue infiltration in the TA of the anterior leg compartment. Study 
4, demonstrated that muscles in the posterior leg compartment, that differ functionally 
from the TA and are innervated by a different portion of the sciatic nerve undergo similar 
morphological changes to the TA. In combination, these neuronal deficits and skeletal 
muscle structural abnormalities likely lead to muscle weakness and functional 
impairment seen in patients with CIDP. Together these studies form a foundational 
understanding of how CIDP impacts both nervous and muscle tissue at a systems level.  
Keywords 
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); peripheral nervous 
system; muscle; human; weakness; motor unit; electromyography (EMG); magnetic 




Summary for Lay Audience 
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an ultra rare immune 
mediated neurological disorder in which there is inflammation of peripheral nerves and 
destruction of the fatty protective covering (myelin sheath) surrounding the nerves, which 
affects how fast the nerve signals are transmitted to their attached muscles. This causes 
weakness, paralysis and/or impairment in motor function, especially of the arms and legs. 
Sensory disturbance may also be present. The motor and sensory impairments usually 
affect both sides of the body (symmetrical), and the degree of severity and the course of 
disease may vary greatly among individuals. Tests that can be of diagnostic help include 
nerve conduction testing and electromyography that demonstrate slow nerve conduction 
velocities, lumbar puncture with evidence of elevated spinal fluid protein and magnetic 
resonance imaging (MRI) of the nerve roots looking for enlargement and signs of 
inflammation. Despite this there is a lack of awareness and knowledge surrounding a 
specific cause and disease mechanism in CIDP making diagnosing the disease very 
difficult. 
To date no studies have systematically investigated the neuronal and musculoskeletal 
consequences of this nerve disease. Therefore, it is critical to study the function of the 
peripheral nerves in this inflammatory disorder as well as their connection to skeletal 
muscle. In this work I investigated two main phenomenon related to CIDP. The first two 
studies of this thesis quantify the loss of motor nerves as well the health of the remaining 
motor nerves in response to the demyelinating process. The two subsequent studies 
investigate the repercussions of motor unit loss on the amount and quality of the muscles 




with CIDP not only have fewer motor units; the remaining motor units are very 
unhealthy. This reduction of motor units in combination with the poor connection these 
motor units have with their attached muscle leads to major losses in the amount and 
quality of muscle tissue. Overall, this work provides compelling evidence for the 
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Chapter 1  
1 General Introduction  
Beginning in the early eighteenth century, neurobiologists attempted to discover a link 
between electricity and how nerves function. Luigi Galvani took the first steps in laying 
the foundation of modern electrophysiology by demonstrating the presence of electricity 
in dissected frogs1. Julius Bernstein and Emil du Bois-Reymond, in 1843 were the first to 
accurately describe a phenomenon called the action potential 2,3.  Throughout the next 
half-century, others went on to show that nerve and muscle tissues generate electrical 
transients that accompany this nervous excitation. Although the field of neuroscience has 
progressed immensely our comprehension of numerous components within 
neuromuscular physiology continue to elude our understanding. Specific amongst these, 
are inquiries concerning the influences disease has on nerves and what consequences 
these nerve abnormalities have on connected muscle. A more comprehensive 
appreciation regarding neuromuscular disease processes may ultimately lead to early 
diagnosis or enhanced treatment options allowing individuals with nerve diseases the 
opportunity to mitigate the devastating consequences of muscle atrophy.  
1.1 The Neuromuscular System Anatomy/Physiology and the 
Motor Unit in Humans 
1.1.1 Neuromuscular System 
The neuromuscular system, composed of nerves and muscles, provides humans with the 
means to coordinate movement and is essential in controlling posture and gait. 
Specifically, the neuromuscular system is responsible for transmitting signals from the 





circuit of motor neurons and skeletal muscles. Electrical impulses elicited in the motor 
neuron’s cell body propagate along the motor axon and result in the release of 
the neurotransmitter, acetylcholine, from the motor nerve terminal at a synaptic 
connection, termed the neuromuscular junction. The neurotransmitter molecules of 
acetylcholine diffuse across this neuromuscular junction and bind acetylcholine receptors 
on the muscle fiber. The binding results in the opening of ion channels within the muscle 
fiber, thus altering the muscle membrane potential. This muscle membrane depolarization 
then triggers a release of internal calcium ions that leads to a cascade of events resulting 
in skeletal muscle contraction 4. The neuromuscular system is substantially more complex 
than outlined above and many questions remain unanswered. Investigation of 
modifications to nerves and muscles due to disease (e.g. demyelinating polyneuropathies) 
can provide useful insight into basic neuromuscular pathophysiology and the mechanisms 
responsible for the functional limitations seen in patients. Of most interest to the study of 
neuromuscular diseases and the focus of this dissertation is this vital connection between 
the nerves and their accompanied muscle.   
1.1.2 The Motor Unit 
A single motor unit is composed of an individual motor axon called an α-motor neuron, 
and all skeletal muscle fibres innervated by this distinct axon. In humans there are two 
major types of motor units: type I and type II. Fundamentally, small motor units have 
smaller axon diameters, fewer fibers that make up the complete unit, and are more 
resistant to fatigue. These motor nerves innervate slower muscle fibers and are referred to 
as type I motor units. Large motor nerves innervate larger, faster muscle fibers that are 





fibers in a specific motor unit is directly correlated to the size of the motor neuron for that 
unit 
5
. The size of a motor unit is defined by the number of muscle fibres it innervates and 
varies significantly in different motor units from dozens of muscle fibres per unit to 
thousands of muscle fibres per unit (Figure 1.1) 6.  
A small motor unit’s cell body located in the ventral horn of the spinal cord has a low 
excitation threshold to cause an action potential. Therefore, less excitation input is 
required for small cell bodied neurons and a motor unit that has a smaller cell body also 
has a smaller nerve fiber that innervate fewer muscle fibers when activated. For this 
reason specifically, smaller, type I motor units are more easily discharged and are also 
more impervious to fatigue. Conversely, larger type II motor units can activate hundreds 
of muscle fibers collectively with a single action potential from a motor neuron 7. Due to 
their direct relationship, muscle fibers are commonly referred to by their motor unit type.  
  




















Two separate motor units are depicted (Type I and Type II). α-motor neuron cell bodies are located in the 
ventral horn of the spinal cord. The axon exits the ventral horn into the periphery and synapses with their 
respective muscle fibers at the neuromuscular junction. Each motor unit is composed of an individual α-
motor neuron and all attached muscles fibers. Adapted from: Ko 2001 4 
Skeletal muscles composed of smaller motor units are capable of finer, more accurate 
control. This would be advantageous for small muscles required for refined movements 
such as muscles in the hand. Alternatively, motor nerves innervate larger muscles 
responsible for gross or powerful movements 8,9. The force exerted by a muscle during a 
voluntary contraction depends on the number of motor units that are activated and the 
rates at which these motor units discharge action potentials. These two properties of 
voluntary contractions are known as recruitment and rate coding. At low levels of 
voluntarily muscle contraction, smaller type I motor units are generally recruited prior to 
larger type II motor units, a concept referred to as the Henneman size principle 
6,8
. The 
Henneman size principle states that the recruitment of motor units within a muscle 
proceeds from small motor units to large motor units. Small motor units have low 
thresholds of activation and are recruited first. Larger motor units with higher thresholds 
of activation follow are recruited later 
10
. 
In contrast, rate coding refers to the modulation of motor unit action potentials whereby 
the force of a muscle fibre is modified by increasing or decreasing the frequency at which 
motor neurons discharge to their coupled muscle fibres 11. Experimental evidence 
suggests that recruitment is the more significant factor at low forces, whereas rate coding 





1.2 Schwann Cells, the Myelin Sheath and Saltatory 
Conduction 
Schwann cells are derived from neural crest cells, and are of two types: myelinating or 
non-myelinating Schwann cells. Myelinating Schwann cells form a tightly wrapped lipid 
bilayer that surrounds the motor axon composed of specialized protein constituents and is 
structurally and electrically critical for the propagation of nerve impulses and axonal 
maintenance 12. Schwann cells also play a pivotal role in maintaining the nervous system 
and are vital in motor axon regeneration. The presence of myelin along the length of the 
α-motor neuron is essential to maintain conduction velocity; its loss or damage can lead 
to significantly slower conduction or conduction block. In certain peripheral 
neuropathies, electrical propagation blockade may be the preliminary event in the cascade 
of events leading to the loss of Schwann cells in a process called demyelination 14.  Along 
the length of an α-motor neuron the myelin sheath formed by Schwann cells is 
interrupted at regular intervals (nodes of Ranvier) where the axon membrane containing 
voltage gated sodium channels is exposed to the extracellular environment 14. The 
propagation of action potentials along the length of motor axons relies on the 
collaborative action of these membrane-spanning selectively permeable ion channels 15. 
Specifically, myelinated α-motor neurons feature an extremely organized distribution of 
voltage-gated ion channels, with a characteristic clustering of Na+ channels at the nodes 
of Ranvier. Saltatory conduction in myelinated axons refers to the rapid propagation of 
the electrical waveform from each node to the next. In this process myelinated axons only 
permit action potentials to transmit at the unmyelinated nodes of Ranvier. This ionic 
restriction allows saltatory conduction to propagate an action potential along the motor 





As sodium rushes into the node it creates an electrical diffusion gradient, which drives 
the ions contained within the axon’s cytoplasm 16.  This rapid conduction of ionic 
signaling reaches the next node and generates another action potential, thus revitalizing 
the electrical signal (Figure 1.2). In this manner, saltatory conduction allows electrical 
nerve signals to be propagated along the axon length almost instantaneously without any 
degradation of the signal 16,17,18. Focal disruption (segmental demyelination) of 
the myelin sheath can lead to failure of impulse conduction in the denuded axon segments 
(termed conduction block) in part because of a paucity of voltage-gated sodium 







Figure 1.2 Saltatory conduction 
Schematic depicts an action potential propagation down the length of an axon by method of saltatory 
conduction. As sodium rushes into the node it creates an electrical force that pushes on positively charged 
ions already inside the axon. This rapid conduction of electrical signal reaches the next node and creates 
another action potential refreshing the action potential. Saltatory conduction allows electrical nerve signals 
to be propagated at high rates, long distances. Adapted from: Rash et al 2016 18 
1.3 Chronic Inflammatory Demyelinating Polyneuropathy 
(CIDP) 
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological 
disorder characterized by inflammation of nerve roots and peripheral nerves and 





of CIDP ranges from 0.7 to 10.3 cases per 100,000 people 19. CIDP primarily affects 
adults and the incidence rises with advancing age. Although not well established there 
seems to be a male predominance and an age of onset is not known. No specific 
predisposing factors for CIDP have been identified 20. There is heterogeneity in clinical 
phenotypes in CIDP, and it may not be a discrete disease entity but rather a spectrum of 
discrete albeit related conditions. Commonly reported phenotypes of CIDP include motor 
and sensory nerve dysfunction, with motor deficits reported in up to 94% of patients and 
sensory deficits in up to 89% 21. The prognosis of CIDP is variable and is reminiscent of 
multiple sclerosis in its heterogeneity. Some patients (20-65%) 22 follow a relapsing 
remitting course, others a more progressive course. Over time, most patients without 
associated confounding conditions respond to treatment.  
1.3.1 Clinical Diagnosis  
The diagnosis of CIDP depends on a combination of clinical and electrophysiological 
criteria. The European Federation of Neurological Societies (EFNS)/Peripheral Nerve 
Society (PNS) guidelines were developed for clinical and research use 22. The EFNS 
criteria combine clinical features in combination with electrophysiological evidence to 
define CIDP. In addition to the guidelines, supportive criteria include: elevated 
cerebrospinal fluid (CSF) protein, gadolinium enhancement of nerve roots or plexus on 
magnetic resonance imaging (MRI) in addition abnormal nerve biopsy findings provide 
complementary diagnostic evidence. In abnormal nerve biopsies thinly myelinated large 
axons are most frequently observed. Importantly, electrodiagnostic evidence of peripheral 
nerve demyelination specifically in motor nerves is required for diagnosis. Segmental 





lead to onion bulb formations by proliferation of Schwann cell processes covering motor 
axons. 
For a definitive diagnosis of CIDP the following electrophysiological indications must be 
identified in at least two nerves: latency prolongation, reduction of motor conduction 
velocity, prolongation of F-wave latency reduced compound muscle action potentials 
(CMAPs), and partial motor conduction block 22. The features of CMAPs and conduction 
block and how they pertain to CIDP will be discussed in greater detail below. Clinical 
patient workup includes muscle strength evaluation (MRC 0-5 scale), Overall 
Neuropathy Limitations Scale (ONLS) score, ataxia score and 10‐m walk test. Other tests 
and functional scales are used depending on symptoms (grip test, nine‐hole peg test, and 
Inflammatory Neuropathy Cause and Treatment Sensory Sum Score). Although, other 
diagnostic guideline criteria have been suggested the EFNS/PNS criteria have 
demonstrated sensitivity and specificity for CIDP diagnosis and are currently the most 
commonly used 23, 24. 
1.3.2 Differential Diagnosis 
CIDP is distinguished from acute inflammatory demyelinating polyradiculoneuropathy 
(AIDP) in that it is a monophasic disorder with nerve damage due to an immune response 
to a single (infectious) event as well as treatment responsiveness. Unlike AIDP, CIDP 
typically has a more indolent course and published criteria for CIDP recognize time to 
greatest weakness of longer than 8 weeks as the defining feature that differentiates CIDP 
from AIDP 19. CIDP disease presentation is usually classified into three subtypes. A 





immediacy and type of treatment. A recurrent form that has episodes of symptoms that 
starts and stops over time and lastly a monophasic form.  The monophasic form is defined 
as a single bout of the disease that has a duration of one to three years, but does not ever 
recur 22.  CIDP is often misdiagnosed as Guillain-Barré Syndrome (GBS), the most 
common form of AIDP, and for this reason finding more robust diagnostic criteria is 
critical to proper disease diagnosis and prognosis.  
1.3.3 Pathology of CIDP 
The principal theory of CIDP pathogenesis is that cell-mediated and humoral 
mechanisms act synergistically to cause damage to the peripheral nerves. Several lines of 
evidence support the conclusion that CIDP is an autoimmune disease mediated by 
cellular immunity against yet to be undefined Schwann cell myelin protein antigens. 
Some patients have reported infections prior to onset of neurological symptoms, however 
no specific trigger for the autoimmune response has been identified and no infectious 
agent has been consistently linked with initiation of CIDP 25. There have been some 
recent advances in the area of the pathophysiological significance of autoantibodies 
directed specifically towards the nodal regions of peripheral axons in patients with CIDP. 
It has become clear that the anatomical and the molecular complexity of the node of 
Ranvier affects the ability of antibodies to bind and is the likely pathogenicity of the 
immune response in CIDP. In a normal, healthy axon, the myelin sheath wraps around 
the axon and ion channels are clustered in the unmyelinated nodes of Ranvier. This 
enables Saltatory conduction down the length of the axon. In CIDP, there is systemic 
infiltration of T-cells, B-cells, plasma cells, and macrophages, which lead to a cascade of 





destructive to both the myelin and axons (Figure 1.3).  Axonal damage and 
neurodegeneration occur simultaneously with focal inflammation. There is ongoing 
demyelination due to antibodies against myelin antigens. Demyelination leads to the 
redistribution of ion channels, which impairs conduction along the axon. It is a 
combination of these events, rather than one in particular that contributes to 
neurodegeneration and axonal damage in CIDP 25,26. 
 
Figure 1.3 Axonal damage in CIDP 
(1) Depiction of a healthy axon, the myelin sheath (blue) wraps around the axon and Na ion channels 
(orange) are clustered in the unmyelinated nodes of Ranvier. This enables saltatory conduction down the 
length of the axon. (2) Systemic infiltration of T-cells, B-cells, (purple cells) plasma cells (green cells), and 
macrophages (aqua cells) leading to a release of pro-inflammatory cytokines and antibodies (black and blue 
Y) that are destructive to both myelin and axons. (3) Ongoing demyelination due to antibodies against 
myelin antigens leads to the redistribution of ion channels that impairs action potential conduction along 
the axon. Adapted from: Salapa et al 2017 27 
A combination of MRI, ultrasound and autopsy studies have established that the 
inflammatory lesions in CIDP arise predominantly in the spinal roots, proximal nerve 






trunks and major plexuses and are often spread throughout smaller peripheral nerves 25,26. 
However, due to the inaccessibility of proximal nerves and nerve roots for diagnostics, 
most clinical nerve biopsies are obtained from the sural nerve. Although the sural nerve is 
peripheral and located furthest from the most prominent inflammatory activity in the 
proximal nerve roots, pathophysiological changes in sural nerve biopsies reflect the broad 
spectrum of changes seen in CIDP. Pathological observations in sural nerve biopsies 
include demyelination, formation of onion bulbs, oedema, perivascular or endoneurial 
macrophage inflammatory infiltrates and T cells and axonal degeneration 25,26. In blood 
and CSF of patients with CIDP studies have shown changes in the function and 
abundance of T cell subsets, altered expression of cytokines and other inflammatory 
mediators 28,29,30. An animal model of CIDP called experimental autoimmune neuritis 
(EAN), demonstrates similar pathological changes to those observed in humans. This 
animal model of CIDP is induced in susceptible strains of rodents or rabbits by 
immunization with specific myelin proteins and is the result of an autoimmune attack on 
peripheral nerves mediated by macrophages and T-cells 31.  
1.3.4 Treatment of CIDP 
There are three conventional treatments prescribed for CIDP. Glucocorticoid drugs such 
as prednisone have proven effective in large patient trials. In many cases, individuals 
with CIDP may respond to glucocorticoid treatment alone 32. However, individuals 
requiring high doses of glucocorticoid drugs may experience side effects that deter long-
term therapy. Steroid drugs only act to reduce the inflammation and their long-term use 
in patients with CIDP has not been well-established 32. Intravenous immunoglobulin 





CIDP either alone or concurrently with glucocorticoids 33,34. IVIG acts to suppress the 
proliferation of antigen-specific T cells, which diminishes the autoimmune insult on 
peripheral nerves. Lastly, plasma exchange (PE) has been shown in clinical trials to 
benefit individuals with CIDP 33. The process of PE involves removing whole blood from 
an individual with CIDP and red blood cells are subsequently separated from plasma. The 
plasma is then replaced with healthy human plasma and the patient’s blood cells are 
transfused back into the systemic circulation, thus removing only the plasma and its 
constituents. Importantly, IVIG and PE are effective only for a few weeks and may 
require chronic intermittent refresher treatments.  
1.3.5 Functional Consequences of CIDP 
Patients with CIDP can experience motor and or sensory disturbances and when 
combined can exacerbate functional consequences of the disease. Briefly, most 
individuals with CIDP experience some alterations of sensation causing sensory ataxia 
(loss of coordination) and paresthesia.  Some patients only have sensory symptoms and 
signs but demonstrate typical abnormalities of nerve conduction and respond to 
treatment. This is considered the sensory variant of CIDP. Other common more severe 
systemic sensory symptoms include: chronic fatigue, pain, dysphagia, and diplopia. 
Importantly, gait will be abnormal and proprioceptive responses to various environmental 
sensory stimuli will be impaired. In cases of typical CIDP, motor decrements present 
symmetrically in a length dependent fashion with chronically progressive, stepwise or 
recurrent proximal and distal muscle weakness in all extremities. Although it is thought 
that the degree of muscle atrophy in CIDP is generally mild given the general severity 





shown patients to have muscle atrophy particularly in distal musculature 36. Higher 
prevalence of muscle atrophy is reported amongst patients with longer disease durations 
or delayed treatment initiation. In patients with marked muscle atrophy, muscle weakness 
and atrophy primary affect lower extremities, whereas in patients without marked muscle 
atrophy, the upper and lower limbs are equally affected 37. Studies also establish that 
patient functional status (as determined by the MRS) are significantly worse in patients 
with discernable but not quantified muscle atrophy 38. Overall, many individuals with 
CIDP are left with residual muscle weakness, tremors, fatigue, as well other symptoms 
that can lead to diminished quality of life and long-term morbidity.  
1.4 Motor Unit Number Estimations (MUNE) Using 
Decomposition-based Quantitative Electromyography 
(DQEMG) 
Since the early days of neurophysiology research it has been recognized that the loss of 
motor units has been a crucial physiological process fundamental in various 
neuromuscular diseases 
39
 Consequently, it has been of great interest to develop 
methodologies for in vivo quantification of functional motor units in a single muscle. 
Motor unit number estimate (MUNE) was developed to quantify the number of motor 
units in a specific muscle. Early MUNE techniques were developed to circumvent the 
limitations associated with standard clinical electrophysiological techniques, which only 
provided a qualitative physiological assessment of functional motor units. Since the 
original establishment of MUNE, the technique has been vastly improved 
39,40 
. In recent 
years, powerful digital signal processing capabilities have provided the impetus for 





number of functioning motor units in vivo 
41
. MUNE is established upon the ratio 
between a maximal compound muscle action potential (CMAP) that is divided by a mean 
surface motor unit potential (SMUP) 42. The CMAP signifies the absolute maximal 
electrophysiological size of the complete motor unit population within a muscle. The 
mean SMUP characterizes the absolute size of the average representative sample of a 
single motor unit 34.  Currently no gold standard methodology exists regarding counting 
human motor units or motor axons even with in vitro immunohistochemistry 
preparations.  
Decomposition-based quantitative electromyography (DQEMG) is the quantitative in 
vivo assessment of motor unit action potentials from individual motor units and can 
provide valuable information in assessing the integrity of human motor units 
42
. DQEMG 
incorporates a combination of intramuscular electromyography (EMG) and surface EMG 
to decompose complex EMG patterns into individual motor unit action potential trains 
 
41,43
. This allows DQEMG software to deliver more detailed information for each motor 
unit train such as: motor unit size, shape, stability and most importantly the DQEMG 
software is used to acquire an estimate of the number of functioning motor units within a 
single muscle 44,45. DQEMG uses two sources of EMG (micro and macro signals) to gain 
insightful information regarding specific motor unit characteristics 
45
. Micro signals are 
gathered through intramuscular needle EMG electrodes. These micro EMG signals are 
usually collected via concentric needle electrodes during sustained 30-second volitional 
isometric contractions 44,45. Originally this micro needle EMG signal, collected through 
low to moderate level muscle contractions, consists of complex EMG interference 





algorithms to decompose this complex micro EMG pattern into constituent individual 
motor unit action potential trains. Each action potential train belonging to a single motor 
unit is classified based on shape and firing rate variability 43,44,45. Macro (surface EMG) 
signals are collected via surface electrodes, and provide EMG information regarding the 
overall size and spatial distribution of active individual motor units. By using each 
individual micro needle motor unit action potential train as a trigger for the macro signal, 
the macro signal is temporally aligned with the decomposed micro needle signal. Time 
locking of the macro EMG signal to the micro needle detected action potentials, allows 
for the derivation of SMUPs, which resemble the corresponding size of individual motor 
units within an active muscle and are used as the denominator in the MUNE calculation 
40.  
Using DQEMG software to calculate a MUNE has been reported with high degrees of 
intra- and inter-rater reliability
 46,47,48,49
. Numerous studies have shown that contraction 
intensity has a discernible effect on DQEMG derived MUNE calculations 50. Studies 
executed in different muscles have found that with increasing contraction intensities 
mean SMUP size increases, which inversely decreases the MUNE for that specific muscle 
51.  One study concluded that a contraction intensity of 25% of maximum voluntary 
contraction (MVC) in the tibials anterior (TA) muscle, recruits a representative sample of 
low (type I) and high (type II) threshold motor units and thus provides the most 
representative motor unit number estimation in the TA muscle 51,52. Importantly, 
DQEMG also conveys detailed electrophysiological data regarding the morphological 
characteristics of individual needle detected motor unit action potentials 
41,42
. 





variability, motor unit action potential size (area and amplitude), motor unit action 
potential shape and complexity (turns, phases) and motor unit discharge stability (jitter, 
jiggle, and % blocking).  
Increases in motor unit action potential complexity as well increased action potential 
amplitude are electrophysiological indications of enlarged, collaterally reinnervated 
motor units, which have been associated with numerous neurological disease processes 
49
. Motor unit action potential stability signifies the integrity of neuromuscular 
transmission, either at the neuromuscular junction (NMJ) or within the muscle fibre itself. 
This motor unit stability is examined through the detailed assessment of the variability in 
shape of each consecutively detected action potentials. There are two key motor unit 
stability properties associated with shape variability termed jitter and jiggle 52,53,54.  Jitter 
represents the variability in the time intervals between pairs of individual muscle action 
potentials from a single motor unit, and jiggle refers to the overall variability in motor 
unit action potential shape from one discharge to the next 55,56 (Figure 2.1). Abnormal 
neuromuscular stability, specifically increased jitter and jiggle have been detected in 
conditions that involve neuromuscular transmission interruptions and are indicative of 
early axonal denervation 
55,56
. Lastly DQEMG provides a measure of the percentage of 
motor units that are blocked.  Percent (%) blocking is a measure of unsuccessful motor 
unit action potential transmissions in a muscle fibre or axon and is a clinically prominent 
feature of many demyelinating diseases 56. Most clinical diagnostic EMG studies are 
performed at minimal submaximal contraction intensities, which severely limit clinical 
needle EMG assessments to moderately few and entirely low threshold (type I) motor 





delivers an irreplaceable and appropriate paradigm in combination with needle detected 
motor unit action potential examination and MUNE measures to gain a more 
comprehensive understanding of the pathological changes to motor units that underlie 
nerve dysfunction in CIDP. 
1.5 Intramuscular Needle Electromyography 
During voluntary contractions, the central nervous system regulates muscle force by 
changing the number of motor units recruited. As discussed above additional force 
regulation is achieved by varying the individual motor neuron firing rates. Once 
maximum force has been established, no useful purpose is served by any further increase 
in motor neuron discharge frequency. In recent years, the precise measurement of 
individual motor-unit firing rates during voluntary contractions became possible using 
tungsten micro- electrodes 57,58. Tungsten microelectrodes provide a high signal-to-noise 
ratio, allowing clear identification of single muscle fibre action potential trains even at 
the highest forces. Briefly the tungsten micro electrode consists of a 5 cm long, 0.2-mm 
diameter needle with an insulated tungsten shaft and a 10-15um exposed tip. For 
successful recording of single muscle fibre action potentials with a high signal-to-noise 
ratio, an electrode impedance greater than 100 Ω is generally required 59. The tungsten 
electrode is inserted through the skin until the tip is directly below the muscle surface. As 
a subject volitionally contracts, the needle is further slowly and progressively advanced 
(typically l-3 mm at each contraction) such as to record trains of potentials from as many 
muscle fibres as possible (see Figure 3.1) 59. The advantage of the tungsten technique 
over using conventional recording electrodes and DQEMG, is the isolation of single-unit 





techniques since the potentials arising from single units are not clearly distinguished from 
each other at forces exceeding 75-80% MVC 58,59,60.  Numerous studies in neuromuscular 
diseases such as Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS) have 
used this intramuscular tungsten technique to quantify motor unit firing rates resulting 
from targeted axonal damage 61,62. Results from the tibialis anterior muscle in patients 
with ALS indicate that the physiological modulation of motor neuron firing rate is 
decreased as well the variability of MU discharges tends to be greater in this disease 63. 
Only a minutia of clinical data exists regarding motor unit firing rates in CIDP, most of 
which only records from early recruited motor units and to date there have been no 
systematic studies investigating motor unit firing behaviour in individuals with CIDP 
especially at maximal firing rates. 
1.6 Magnetic Resonance Imaging (MRI)  
Magnetic resonance imaging (MRI) is a medical imaging technique used to form images 
of the internal structures and anatomy.  MRI works by using the magnetization properties 
of the atomic nuclei. This imaging technique employs a uniformly powerful external 
magnetic field, which aligns the protons that are normally randomly oriented within 
water nuclei of the tissue under examination. This alignment called magnetization is than 
perturbed or disrupted by introducing energy from an external Radio Frequency (RF) 64. 
After being perturbed the atomic nuclei return to their resting alignment through a 
relaxation processes, which emits RF energy that is measured for a specified period of 
time. The signal from the internal structures contain location information and are sorted 





arrangement of pixels.  The sequence or frequency of RF pulses applied and collected can 
create different images.  
Repetition Time (TR) is the amount of time between successive pulse sequences applied 
to the same slice of tissue and Time to Echo (TE) is the time between the delivery of the 
RF pulse and the receipt of the echo signal 64,65. The different human tissue types can be 
characterized by two different relaxation times T1 and T2. T1 or longitudinal relaxation 
time is the time constant which determines the rate at which excited protons return to 
equilibrium. This is a measure of the time taken for spinning protons to realign with the 
external magnetic field. T2 or transverse relaxation time is the time constant, which 
determines the rate the excited protons reach equilibrium or go out of phase coherence. 
There has been a growing interest in MRI assessment of the peripheral nervous system in 
dysimmune or autoimmune neuropathies, especially in patients with CIDP 66,67,68.  
The first reported descriptions of nerve abnormalities, using conventional MRI was in the 
1990s. Since then, higher strength and advanced MRI imaging sequencing techniques 
have enabled a better discrimination of the peripheral nervous system and a better 
characterization of nerve abnormalities. Typical MR findings in CIDP include 
nerve enlargement, T2 signal increase and enhancement of nerve roots, especially in the 
early stages of the disease when inflammation tends to be unmanaged 67,68. Proximal 
nerve involvement is typical at the onset of CIDP and becomes more prominent and 
ubiquitous in the long-term. Imaging studies show nerve enlargement is positively 
correlated with disease duration 67,68. However, correlation of MRI features with clinical 
disability seen in patients with CIDP, specifically functional losses of strength, are still 





the spinal nerve roots and proximal nerve trunks, and there is a paucity of work 
investigating the muscles that connect to these peripheral nerves. Importantly with the 
advancement in imaging techniques the distal extremities can be imaged with smaller 
surface coils reaching greater resolution. This allows direct and definitive visualization of 
skeletal musculature affected by demyelinated peripheral nerves seen in patients with 
CIDP.  It is critical to investigate the degree of muscle atrophy associated with CIDP as 
well to quantify the infiltration of non-contractile tissue to help elucidate reasoning 
behind function muscle weakness in patients with CIDP.  
1.7 Purposes and Hypotheses  
The fundamental objective of the studies characterized within Chapters 2, 3, 4, and 5 was 
to examine the pathophysiological effects of CIDP on the human neuromuscular system. 
Previous investigations in CIDP have minimally explored the impacts of demyelination 
on axonal function and none to date has focused on the fundamental consequential 
changes to skeletal muscles innervated by chronically demyelinated nerves.  In Chapter 2 
the purpose was to determine if the loss of strength reported in patients with CIDP is 
related to a loss of motor units. Furthermore, I wanted to assess motor unit functional 
stability as quantified using DQEMG. It was hypothesized that patients with CIDP would 
have fewer and less stable motor units compared to healthy controls, and decreased 
MUNEs would be related to loss in strength observed in patients with CIDP.  
The purpose of Chapter 3 was to investigate the specific motor unit firing patterns of 
demyelinated and remodelled motor units.  Commonly, clinical data are recorded from 
small, low-threshold, early recruited motor units. However, it is not known how larger 





by disease demyelination and inflammation. If patients with CIDP have disruptions to 
motor unit firing patterns, that could further explain functional weakness. It was 
hypothesized that motor unit firing rates would be depressed at all levels of voluntary 
contractions in individuals with CIDP due to chronic peripheral nerve demyelination and 
conduction block.  
To date, the vast majority of studies investigating nerve dysfunction focus on evidence of 
demyelination or nerve lesions detectable via imaging. Very few studies have focused on 
the repercussions of CIDP on the quantity and quality in the associated musculature. 
Therefore, the purpose of Chapter 4 was to determine how motor unit loss, instability and 
blocking affect the tibialis anterior musculature of patients using a general anatomical 
scan (T1) as well spin-echo (T2) MRI sequences. It was hypothesized that patients with 
CIDP would feature a greater degree of tibialis anterior muscle atrophy as well larger 
infiltrations of non-contractile tissue.  
The purpose of Chapter 5 was to assess if nerves that supply the posterior leg muscles are 
affected by the demyelinating process to the same degree as the nerves supplying the 
anterior leg and if this leads to differences between compartments and muscles in overall 
composition. It was hypothesized that patients with CIDP would have uniform alterations 
both in the anterior and posterior musculature of the leg and proportions of non-
contractile intramuscular tissue would be homogeneous in the two compartments.   
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Chapter 2  
2 1Electrophysiological And Neuromuscular Stability Of 
Persons With Chronic Inflammatory Demyelinating 
Polyneuropathy (CIDP) 
2.1 Introduction 
 Chronic inflammatory demyelinating polyneuropathy (CIDP) is a generalized 
neuropathy of immunological origin. It is as a heterogeneous disease of symmetrical 
muscle weakness, which includes sensory and motor deficits in both proximal and distal 
limbs that progressively increases for >2 months 1. The condition is associated with 
absent or diminished tendon reflexes, signs of demyelination, elevated cerebrospinal fluid 
protein level, impaired sensation, slow nerve-conduction velocity, and distal muscle 
weakness 2. In inflammatory polyneuropathies such as CIDP, early diagnosis and therapy 
may not only mitigate progression of demyelination but also prevent secondary motor 
unit (MU) loss, which is often responsible for persisting motor symptoms. Therefore, a 
better understanding of the degree and time course of loss and stability of functioning 
MUs due either to primary or secondary demyelination 3 in CIDP would provide more 
insight into the pathophysiology of the disease and possibly improve functional 
outcomes. CIDP affects men and women of all ages and has a population prevalence of 3 
per 100,000 people 4,5.   
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Diagnosis is based on history, clinical examination including electromyography and 
nerve conduction studies, blood tests, cerebral spinal fluid, and in some cases nerve 
biopsies.  
Further diagnosis of CIDP is confirmed by the elimination of other neurological diseases 
such as diabetic polyneuropathy and inherited demyelinating polyneuropathies. Although 
the electrophysiological and neuromuscular properties of persons with CIDP have been 
described above, details of undesirable alterations in motor unit structure and function 
that could explain weakness and related functional changes have not been quantified 
systematically. Although exact mechanisms are not understood entirely, limited evidence 
in autoimmune neuropathies indicates that disease related to pre or post-synaptic damage 
and muscle fiber atrophy lead to neuromuscular junction remodeling and impaired 
neuromuscular transmission 6. It is presumed that in autoimmune neuropathies such as 
CIDP, MU death or axonal damage is followed by variable reinnervation by collateral 
sprouting and axonal outgrowth, both of which could add to neuromuscular transmission 
instability 7. In routine clinical nerve conduction studies, a compound muscle action 
potential (CMAP) is recorded, but the CMAP features alone do not quantify the extent of 
motor unit loss or dysfunction because of the possible compensatory effect of 
reinnervation. The technique of decomposition-based quantitative electromyography 
(DQEMG), however, can be used to assess any loss of motor neurons and cardinally 
detect the increase of motor unit size due to collateral reinnervation. DQEMG has also 
been shown to be a reliable and valid tool for obtaining information regarding MU 





other neuromuscular diseases and neuropathies, such as ALS and diabetic neuropathy 
8,9,10,11,12.  
A few studies in CIDP, using single fiber EMG (SFEMG) in upper limb muscles have 
shown increased fiber density along with neuromuscular instability, but no studies have 
investigated lower limb muscles using the DQEMG technique in CIDP patients. This 
technique can extract beneficial information regarding the MU pool from simultaneously 
acquired surface and concentric needle-detected signals 13. Furthermore, in conjunction 
with a maximal CMAP amplitude, DQEMG can be utilized to calculate a motor unit 
number estimate (MUNE). This measure provides critical insight about the innervation 
status of a muscle 10,14. Near-fiber (NF) parameters such as jiggle, jitter, blocking, and 
area, derived from DQEMG also relate to the integrity or stability of neuromuscular 
transmission 12,15,16, but these measures have not been applied to CIDP. Stability can be 
examined through assessment of the degree of variability in the shape and time of 
consecutively detected motor unit potentials (MUPs) termed “jiggle” and “jitter” 
respectively 17.  
Indeed, the assessment and understanding of these features could potentially be helpful 
for treatment monitoring to aid in disease understanding. MUP shape variability 
parameters and conduction blocking may provide valuable information regarding MU 
health in CIDP during disease progression. Using these techniques, we evaluated the 
magnitude of demyelination, collateral reinnervation following MU loss, and the stability 
of neuromuscular transmission in patients with CIDP. The purpose of this study was to 
assess the neuromuscular stability of the MUs in the tibialis anterior (TA) muscle of 





control group. We chose to focus on the dorsiflexor muscle group, because there are 
comparative data available from several studies of MU properties in aging using this 
muscle group and these techniques 18,19. In addition, adequate dorsiflexor function is 
critical for balance and gait and thus relate to falls risk 18. When compared with controls, 
we hypothesized that patients with CIDP would feature reduced MUNEs, as well 
significantly fewer stable MUs in the TA.  
2.2 Methods 
2.2.1 Subjects  
Ten subjects (7 men, 3 women; ages 47–77 years) with CIDP volunteered for this study 
as well 10 healthy control subjects (7 men, 3 women; ages 57–75 years). History, clinical, 
and electrophysiological features confirming a diagnosis of CIDP were obtained by an 
experienced neurologist to exclude other causes of nerve dysfunction (i.e. 
radiculopathies, other polyneuropathies, or compressive mononeuropathies). Patients 
with any other neurological, metabolic (including diabetes) or vascular diseases (other 
than related to CIDP) were not included in this study (Table 1). All 10 patients underwent 
a clinical electrophysiological examination that assessed bilateral fibular, tibial, ulnar, 
and median motor nerves and bilateral sural, ulnar, and median sensory nerves. Limb 
temperature was monitored during standard electrodiagnostic testing and, if necessary 
limbs were warmed to a minimum of 32 degrees Celsius in the upper limb and 30 degrees 
in the lower limb. Additionally, all patients with CIDP underwent measures of nerve 
conduction velocities (CV), compound muscle action potentials (CMAP), and sensory 
nerve action potentials (SNAP) and compared to normal values. Patients had standard 





dispersion, multifocal conduction velocity slowing, and F-wave prolongation. Moreover, 
CSF analysis revealed elevated protein in the absence of any other abnormality. 
Furthermore, all patients had a clinical presentation consistent with CIDP without 
evidence of alternative diagnosis (i.e. paraproteniemic neuropathies, multifocal motor 
neuropathy or polyneuropathies). All 10 patients with CIDP received usual medical care 
and responded to treatment with intravenous immunoglobulin (IVIG), plasma exchange, 
or prednisone. The local university research ethics board approved the study, and 
informed written and oral consent were obtained from all participants preceding testing.    
2.2.2 Dorsiflexor Strength and Tibialis Anterior DQEMG Data 
Acquisition  
Subjects were seated in a custom isometric dynamometer designed to measure 
dorsiflexion and plantar flexion function 20. The right leg was tested, and the ankle was 
positioned at 30° of plantar flexion, with both knee and hip angles maintained at 90°. A 
C-shaped brace was placed firmly over the distal aspect of the right thigh proximal to the 
patella to secure the leg and foot in the device for recording isometric contractions. 
Additionally, over the dorsum of the foot, inelastic Velcro straps were firmly fastened to 
secure the foot to the dynamometer 19. Subjects first performed a total of 3 dorsiflexion 
maximal voluntary contractions (MVCs), with a minimum of 3 min of rest between each 
attempt. Each MVC was held for 3-5 s. Real time visual feedback was provided to the 
subjects via a 24 inch LCD monitor. Subjects were also strongly encouraged verbally 
during all contractions to ensure maximal effort. Voluntary activation during the second 
and third MVC efforts was assessed using the interpolated twitch technique 21. This 





percutaneous electrical stimulation of the common fibular nerve distal to the head of the 
fibula using a bar electrode. The peak amplitude of the interpolated torque electrically 
evoked from a single 100μs stimulus during the plateau of the MVC was compared with 
the torque produced using the same pulse delivered 1s following the MVC when the 
muscle was at rest. Voluntary activation was calculated as a percent using the following 
equation: [1 − (interpolated twitch /resting twitch)] × 100. The ITT provides an indication 
of the voluntary ability of subjects to produce maximal dorsiflexor activation during the 
MVC. Maximal torque for each participant was determined by the peak torque of the 3 
MVC attempts. Torque signals were collected and sampled online at 500 Hz using Spike2 
software (Version 7.11; Cambridge Electronic Design Ltd., Cambridge, United 
Kingdom) and subsequently analyzed off-line to establish voluntary and stimulated 
contractile properties.   
Surface EMG signals were recorded from the TA using self-adhering Ag-AgCl electrodes 
(1 cm × 3 cm). The active electrode was positioned over the TA motor point, 
approximately 7 cm distal to the tibial tuberosity and 2 cm lateral to the anterior border of 
the TA. The active electrode placement was corrected as required to minimize the rise 
times and to maximize the TA CMAP negative peak amplitude. The reference electrode 
was placed on the distal aspect of the TA tendon. The ground electrode was positioned 
directly over the patella. DQEMG EMG data were obtained using the identical protocol 
described in detail elsewhere 13,22. To record intramuscular EMG data, a disposable 
concentric needle electrode (Model N53153; Teca Corp., Hawthorne, NY) was inserted 
into the TA, 5–10 mm proximal or distal to the active surface electrode. Surface and 





to 10 kHz, respectively. Intramuscular EMG signals were sampled at 30 kHz, and surface 
EMG signals were sampled at 3 kHz. In order to evoke a maximum TA CMAP, a bar 
electrode positioned distal to the fibular head delivered supramaximal electrical stimuli 
(i.e., 125% of the intensity required to achieve a plateau in amplitude) to the common 
fibular nerve. Subsequently, participants matched a dorsiflexor target line of 25% MVC 
for ~30 seconds using a real-time visual torque feed from the LCD monitor, while the 
intramuscular concentric needle electrode was manipulated gently in the muscle. This 
contraction intensity of 25% MVC of the dorsiflexors has been shown to be the most 
relevant level for obtaining a representative MUNE in the TA 19. Intramuscular and 
surface EMG signals were recorded during these ~30s contractions. Between each 30-
second contraction, the indwelling concentric needle electrode was repositioned to 
sample MUs from different regions of the muscle. These methods were repeated until a 
minimum of 20 suitable MUP trains and their respective surface-motor unit potentials (S-
MUPs) were acquired. 
2.2.3 Data Analyses  
Dorsiflexor MVC torque was taken as the highest torque amplitude contraction of the 3 
attempts, and the ITT was calculated as described in methods. In order to establish the 
acceptability of the extracted MUP trains and their corresponding S-MUPs, the 
decomposed intramuscular EMG signals were reviewed off-line. The MUP trains also 
were examined visually to guarantee that their MUP occurrence patterns were consistent 
with the anticipated electrical activity of a single motor unit (inter-discharge interval 
duration coefficient of variation of <0.3 and a consistent firing pattern). Invalid MUP 





DQEMG algorithm calculates a MUP and S-MUP template waveforms and automatically 
places markers linked to onset, negative peak, positive peak, and end positions with 
respect to the MUP template, and onset, negative peak onset, end, negative peak, and 
positive positions with respect to the S-MUP template. To ensure accurate marker 
placement, all MUP and S-MUP markers were reviewed visually by the operator. A 
motor unit number estimation (MUNE) was calculated by dividing the maximal negative-
peak amplitude of the CMAP by the mean S-MUP negative peak amplitude 14. These 
MUNE techniques have been reported previously for this muscle 10. The DQEMG 
algorithms additionally provide mean-firing rates (Hz) of discrete motor units based on 
their extracted MUP trains. From these MU firings an overall mean firing rate per subject 
at the relative submaximal target level of contraction (25% of MVC) was estimated. 
Moreover, standard parameters of the MUP template, including peak-to-peak amplitude, 
duration, area, neuromuscular stability, and near-fiber parameters such as jiggle, jitter, 
and percent blocking were automatically computed by the DQEMG system (see below 
for details). MUPs that represent the isolated activity of a single motor unit were selected 
by the algorithms for assessment of MUP stability. The selected sets of isolated MUPs 
were inspected by an experienced operator, and any MUPs that were contaminated by 
activity of other motor units, were removed and replaced by uncontaminated MUPs. Test-
retest and intra-rater and inter-rater reliability are reported to be high in control and 
clinical populations using these DQEMG measures 9,11,23.  
2.2.4 Near-fiber Parameters 
Neuromuscular transmission integrity was determined by evaluating the degree of 





MUP shape variability are termed jiggle and jitter 17. Near-fiber (NF) jiggle refers to the 
variability in overall MUP shape from 1 MUP discharge to the next. Jiggle is a statistic 
that measures the shape variability of MUPs produced by a single MU 12,15. Successful 
MUP shape variability (jiggle) measurement requires the extraction of sets of “isolated” 
MUPs created by a single MU. The activity of MU fibers in close proximity to the 
concentric needle detection surface can be measured to determine MU stability. NF jitter 
refers to the variability of the time intervals between pairs of individual muscle fiber 
potentials from a single MUP 19. Both jiggle and jitter have been reported to be increased 
under conditions of neuromuscular transmission disruption and axonal injury and 
therefore can reflect early axonal denervation 24,25,26. Increases in MUP instability 
(assessed by jiggle and jitter) have been shown to be caused by variability in muscle fiber 
action potential velocity, a finding present in various myopathies 17. Furthermore, % 
blocking was evaluated for all pairs of detected fiber contributions across the sets of 
isolated NF MUPs.  This parameter is calculated by measuring the number of intermittent 
absences of an individual NF contribution to the NF MUPs from the set of isolated 
analyzed NF MUPs 17. All of the abovementioned MUP and NF MUP parameters such as 
duration, dispersion, area, and fiber count were obtained using an intramuscular 
concentric needle electrode and decomposition-based quantitative electromyography 
(DQEMG) software 13.  
2.2.5 Statistics 
Mean values ± standard deviations are presented in the text and tables. All data were 
tested for normal distribution using the Shapiro-Wilk test. Data not be normally 





data that were normally distributed were analyzed using a 1-way ANOVA. The level of 
significance for all tests was set at P > 0.05. To represent the degree of differences 
between groups, effect sizes were calculated using the Cohen D.  
2.3 Results 
Participant characteristics are listed in Table 2.1. The two groups were well matched on 
gender, age, and anthropometric indices.  Patient data indicate electrophysiologic and 
clinical features consistent with a diagnosis of CIDP (Table 2.2). There were no gender 
differences on any parameter measured in this study. Dorsiflexion strength, voluntary 
activation (ITT), standard MUP parameters, and MUNE values are listed in Table 2.3. 
NF MUP parameter values are presented in Table 3. NF jiggle values are listed as a 
percentage. During MVCs, both the patients and controls were able to achieve near-
maximal (>95%) voluntary activation as assessed using the ITT. The patients with CIDP 
had smaller CMAPs compared to controls. Patients also had fewer motor units (−27%) 
and were weaker (−37%) than controls despite being fully activated during voluntary 
efforts. When assessing MU stability, the patients with CIDP had 90% more jiggle and 
44% more jitter indicative of greater neuromuscular transmission instability when 
compared to controls (Table 2.4). Patients also had significant transmission blocking 
compared to controls (400% difference vs 0%, respectively). Patients with CIDP had 
greater: NF area (+26%), NF duration (+55%), NF dispersion (+106%), and maximal NF 
interval (+70%) compared to controls. Patients also had increased (+48%) fiber count. 
Figure 2.1 depicts exemplar data of near-fiber motor unit potential train (MUPT) data 
from control (a) and a subject with CIDP (b). The NF MUP rasters show sequential 





from a single MU. From these results, those with CIDP had significantly less strength but 
were fully activated during maximal voluntary efforts. Patients with CIDP also had 
substantially lower CMAP values and fewer numbers of MUs with increased 
neuromuscular instability and blocking compared with controls. 
Table 2.1 Participant characteristics 
Anthropometric parameters Controls (n = 10) Patients with CIDP 
(n = 10) 
Men/Women 7/3 7/3 
Age (years) 66.5 ± 9.2 60.5 ± 10.3 
Height (cm) 170.0 ± 1.0 170.4 ± 1.2 
Mass (kg) 79.3 ± 13.3 80.5 ± 11.5 
BMI (kg/m2) 26.7 ± 2.9 27.8 ± 4.9 
  






























Response to IVIG 
or Prednisone 
F, 59 8 3/5 3.3    75g/ 3weeks IVIG 
M, 61 22 1/5 1.5   - 80g/ 4 weeks IVIG 
M, 63 6 4/5 0.75    20g/ 3 weeks IVIG 
M, 73 6 4/5 0.6    Plasma exchange/ 
2 weeks, 125 mg 
prednisone daily 
F, 62 5 3/5 0.85   - 55g/ 3 weeks IVIG 
M, 68 3 4/5 0.7  - - 20g/ 2weeks IVIG 
M, 60 12 4/5 -    currently not 
treated 
M, 45 20 2/5 -    20 mg prednisone 
daily 
F, 59 10 5/5 2.9    5mg prednisone 
every other day 





CSF- Cerebral spinal fluid; IVIG- Intravenous immunoglobulin; - represents no value;  - value observed; 
CB - Conduction block; TD - Temporal dispersion, M-Male, F-Female 
Table 2.3 Dorsiflexor strength and tibialis anterior MUP and MUNE parameters. 
Parameter Controls 
(n = 10) 
Patients with CIDP 
(n = 10) 
% Difference 
Dorsiflexion MVC strength (Nm) 33.6 ± 7.7 21.2 ± 2.9* −37% 
Voluntary activation (%) 95  ± 3 95  ± 2 – 
MU firing rates (Hz) at 25% 
MVC 
12.10 ± 1.80 9.8 ± 0.9 −19% 
MUP Vpp (μV) 811.8 ± 233.6 1081.3 ± 259.4* +32% 
MUP duration (ms) 12.6 ± 2.1 18.9 ± 4.6* +47% 
MUP area (μVms) 1443.2 ± 531.4 1636.4 ± 517.8 +13% 
AAR (ms) 1.75 ± 0.2 2.2 ± 0.5* +20% 
Shape width (ms) 0.7 ± 0.1 0.7 ± 0.2 – 
Turns (#) 2.6 ± 0.8 4.1 ± 1.2* +58% 
CMAP (mV) 6.9 ± 0.83 2.9 ± 0.9* −57% 
mSMUP (μV) 73.3 ± 12.8 84.0 ± 20.1 +13% 
MUNE (#) 99 ± 15 72 ± 9.6* −27% 
MVC, maximal voluntary contraction; MU, motor unit; MUP, motor unit potential; Vpp, peak-to-peak 





motor unit potential; MUNE, motor unit number estimate; -, no value. * significant difference vs controls 
(P < 0.05). 
Table 2.4 Neuromuscular transmission stability and near-fiber parameters. 
 
Parameter Controls 
(n = 10) 
Patients with CIDP 
(n = 10) 
% Difference 
Contractions (#) 4.2 ± 0.5 6.6 ± 1.0* +57% 
# of MUPTs/contraction 5.0 ± 0.4 4.1 ± 1.2 -18% 
NF area (kV/s2ms) 6.9 ± 1.9 8.8 ± 1.3* +26% 
NF duration (ms) 3.8 ± 0.6 5.9 ± 1.4* +55% 
NF dispersion (ms) 1.7 ± 0.4 3.5 ± 1.0* +106% 
Max NF interval (ms) 1.0 ± 0.2 1.7 ± 0.5* +70% 
NF fiber count (#) 2.5 ± 0.4 3.7 ± 0.7* +48% 
NF jiggle (%) 34.3 ± 3.7 65.1 ± 7.2* +90% 
NF jitter (μs) 39.7± 9.5 57.1 ± 6.4* +44% 
% Blocking 0.0 ± 0.0 4.1 ± 1.4* +400% 
MUPT - motor unit potential train; NF - near-fiber. * significant difference between patients with CIDP and 













Exemplar data of near-fiber MUPTs raster plots created from accelerated data from a control subject (A) 
and a patient with CIDP (B). The rasters show sequential firings of MUPs. The NF MUP shimmer plots are 
an overlay of MU firings from a single MU. NF jiggle values are shown as a percentage. 
2.4 Discussion  
In this study we found that individuals with CIDP showed marked differences in many 
neuromuscular measures in the tibialis anterior. Despite being age- and gender-matched 
and with equal voluntary activation abilities, dorsiflexor strength was 37% less in CIDP, 
and the TA in patients had 27% estimated fewer motor unit numbers which were 
considerably less stable with greater blocking compared to controls. Our results of 
MUNE and strength parameters are comparable to other studies of diseased 
neuromuscular systems. For example, Allen et al., (2015) 10 reported 60% fewer motor 
units and a 60% difference in strength in a diabetic polyneuropathy population compared 
to healthy controls. The number of motor units estimated by MUNE can be lower either 
because of axonal loss or because of loss of function of selected axons due to conduction 
block. Our data show fewer MUNEs, greater NF jiggle, NF jitter and blocking in patients 
with CIDP in comparison to controls and may reflect the pathological alterations in 
neuromuscular transmission instability or decreased neuromuscular action potential 
propagation (Table 3). Greater neuromuscular transmission instability is believed to arise 
in conjunction with incomplete reinnervation occurring between orphaned muscle fibers 
and their adopted axonal sprouts throughout the course of collateral reinnervation, or with 
partial loss of innervation by a damaged motor axon, 17. Additionally, our data quantified 
neuromuscular transmission failure (i.e., % blocking) in patients compared to controls 
(Table 2.3). This intermittent transmission failure indicates an underlining dysfunction 





and NF jitter. Furthermore % blocking is indicative of the rate at which an individual 
muscle fiber fails to propagate an action potential following activation of its motor 
neuron. However, it is not certain how potential dysfunction at any of these sites (the 
neuromuscular junction, muscle fiber action potential propagation, distal axonal 
branches, or a combination of factors) contribute to decreased neuromuscular stability in 
CIDP.   
Studies using animal models suggest that neuromuscular instability could be due to a 
variety of factors including axon terminal dysfunction 27, nerve demyelination or reduced 
axonal caliber 28, structural changes in the muscle fiber 27,29, ion channel alterations 27,30,31 
and other possible mechanisms. Any of these proposed alterations in muscle fibers could 
potentially adversely impact muscle fiber action potential conduction velocity 32 and 
subsequently affect MUP shape stability. Our findings of increased NF dispersion, NF 
duration, fiber count, and max NF interval in CIDP likely indicate that prior 
compensatory reinnervation has occurred due to muscle fiber denervation 12,33. MUNE 
techniques have been used in several studies of amyotrophic lateral sclerosis (ALS) 
34,35,36. However, there are very few studies conducted specifically on polyneuropathies 
40. Mostly these studies have focused on hereditary polyneuropathies 38,39,40,41. Two 
studies in patients with CIDP that used single fiber EMG (SFEMG) in upper limb 
muscles reported abnormalities and increased fiber density 42,43 and transmission 
instability 42 compared with controls.   Using stimulated SFEMG, another study reported 
that there was intermittent or persistent blocking in the nerve fibers in upper limb muscles 
of patients 44. Moreover, Delmont et al (2016) showed that patients with CIDP have 





technique 45. They suggested the lower MUNIX was a sign of axonal loss or loss of 
functioning axons and an increase in the average motor unit size (SMUP and MUSIX) 
probably due to the compensatory effect of reinnervation. Lastly, another study that used 
MUNIX and multi-point stimulation showed that the MUNIX value was lower in the 
abductor pollicis brevis (APB) muscle when compared with healthy controls in CIDP 7. It 
is not possible to compare directly various MUNE methods and MUNIX because of the 
specific differences in the technical and physiological aspects in each method. MUNIX is 
an “index” which reflects the number of motor units, using the power and area of CMAP 
and interference patterns, whereas DQEMG is more invasive but provides direct 
recordings of MU properties, including neuromuscular stability. Thus, by incorporating 
needle-detected signals our study provides further insight into factors that may affect MU 
function in relation to neuromuscular function and stability that may indicate the degree 
of disease involvement and disease severity.  
Quantification of neuromuscular stability, specifically NF jiggle and NF jitter in patients 
with CIDP, has not been reported systematically. However, in other clinical conditions 
such as ALS, higher jiggle values were found in the small number of MUPs studied 17, 
and in patients with myasthenia gravis higher jiggle values were reported 26. Additionally, 
increased jiggle was found in patients with diabetic neuropathy 12. Our findings of higher 
jiggle in CIDP align with these other studies, although the mechanisms responsible may 
be quite different (i.e diabetic polyneuropathy and CIDP). It has been shown that 
instability in the neuromuscular system negatively affects neuromuscular transmission 
propagation and can have corresponding detriments on strength 12. Our finding that 





showed increases in transmission blocking in myasthenia gravis using SFEMG 46. Our 
data showing increased NF jiggle and NF jitter in patients relative to controls may reflect 
pathological alterations in neuromuscular action potential propagation or neuromuscular 
transmission instability, but it is difficult to ascertain a prime site. Our percent blocking 
results are also similar to Allen et al., (2015) 10, in diabetic neuropathy and indicate 
failures in muscle fibers to propagate their signal after excitation of a spinal motor neuron 
12.  
2.5 Conclusion  
We have demonstrated the utility of concentric needle-derived DQEMG for detection of 
motor unit remodeling and differences in neuromuscular transmission instability when 
comparing patients with CIDP with age and gender-matched controls. This study 
highlights the value of DQEMG as a potential measure that is sensitive to changes not 
currently detectable by standard clinical nerve conduction studies associated with CIDP. 
The results of this study suggest that NF MUP parameters may have usefulness in 
tracking CIDP progression or the degree of physical impairment. The existence of 
neuromuscular transmission failure (i.e. blocking) in patients may have significant 
consequences regarding neuromuscular function under circumstances that stress the 
capacity of the neuromuscular system, such as contractions that are fatiguing.  Finally, 
the outcomes of our study indicate that NF jiggle and NF jitter are valuable indices for 
identification of alterations in the early stages of neuromuscular disease, preceding the 
loss of motor units or onset of muscle atrophy. Further longitudinal studies of patients 
with CIDP undergoing treatment regimens using the stability parameters of jiggle and 
jitter may be helpful in improving the understanding of the disease. 
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Chapter 3  
3 1Abnormal Motor Unit Firing Rates In Chronic Inflammatory 
Demyelinating Polyneuropathy  
3.1 Introduction 
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune mediated 
disorder of peripheral nerves, with predominant motor involvement and progression over 
several months. In some patients with CIDP the disease course is monophasic with 
complete recovery, and in others it can be slowly progressive, or relapsing-
remitting resulting in prolonged morbidity and sometimes-permanent disability 1. Even 
with appropriate treatment, CIDP usually results in multifocal and segmental 
demyelination that induces motor unit (MU) loss over time 2.  The primary goals of 
treatment management are to control the state of inflammation and thus reduce peripheral 
axonal loss and consequential atrophy, weakness and disability.  
It is well established that functioning numbers of motor units as well as the motor unit 
firing rate characteristics influence the generation and control of muscle force, however 
this has not been systematically investigated in patients with CIDP. Skeletal muscle 
composition and some MU physiological properties have been described in Amyotrophic 
Lateral Sclerosis (ALS) including the finding that mean motor unit firing rates were 
higher in patients with dominant lower motoneuron (LMN) dysfunction compared to 
controls.  
A version of this chapter has been accepted for publication in the Journal of the Neurological Sciences   
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Conceivably this was due to compensatory mechanisms needed to achieve the desired 
force accounting for a loss of MUs 3. MU firing rates were lower in patients with ALS 
with dominant upper motoneuron (UMN) features probably due to diminished central 
drive 3. In addition to alterations in mean firing rates, it has been shown that patients with 
ALS have greater motor unit firing rate dysfunction and increased motor unit firing rate 
variability, specifically in ALS patients with dominant UMN dysfunction.  
The few studies focused on MU function, demonstrated that individuals with CIDP have 
fewer MUs than control subjects in the tibialis anterior muscle 2.  Furthermore, severe 
disruptions in action potential propagation have been demonstrated by concentric needle 
detected jitter and jiggle values that were greater than controls, as well as the presence of 
neuromuscular junction blocking 4,2. The losses in motor axons as well as the instability 
seen in the neuromuscular junctions of patients with CIDP may have precipitated the loss 
of total muscle mass and the infiltration of non-contractile tissue in the leg musculature 5. 
Overall, these changes to the neuromuscular system likely contribute to functional 
weakness and disability in individuals with CIDP. 
Functional impairment in patients with CIDP is primarily caused by conduction block 
and chronic denervation that leads to muscle atrophy and weakness. However, in addition 
to this, it is fundamental to study the motor unit firing characteristics to garner a fuller 
understanding of the etiology of muscle weakness in patients with a chronic peripheral 
demyelinating disease. Furthermore, because individuals with CIDP demonstrate a length 
dependency with regard to axonal loss, often affecting gait and balance, we chose to 
investigate a leg muscle, the tibialis anterior. Fewer motor units, skeletal muscle loss as 





reported for this muscle 2 and therefore we expect firing rates to be impaired and 
recruitment of motor units to be the main strategy used for force gradation at higher 
contraction intensities in patients with CIDP. 
3.2 Methods 
3.3 Subjects 
Seven control (4 male/3 female) subjects and eight (6 male/2 female) patients with CIDP 
were recruited for the study (Table 1). All control subjects were healthy, living 
independently and medication free. Control subjects were recreationally active but not 
trained systematically. Exclusion criteria included known neuromuscular or orthopaedic 
disorders of the lower limb, diabetes, excessive alcohol use, caffeine consumption prior 
to participation, and recreational drug use. This study was reviewed and approved by the 
local University's research ethics board for human experimentation and conforms to the 
latest revision of the Declaration of Helsinki. 
3.3.1 Patient Electrodiagnostic Criteria 
All individuals with CIDP were diagnosed based on the criteria established by the 
European Federation of Neurological Societies 6. Patients with any metabolic (including 
diabetes), neurological, or vascular diseases (other than related to CIDP) were excluded 
from this study. Clinical electrodiagnostic evaluation included standard motor studies of 
the median, ulnar, tibial, and fibular nerves. All patients had electrodiagnostic testing and 
all patients demonstrated demyelinating features (increased temporal dispersion, or 
conduction block, onset latencies/conduction velocities in the demyelinating range) at the 





compound muscle action potential (CMAP) amplitudes, nerve conduction velocities, and 
sensory nerve action potential amplitudes (SNAP) were compared to normative values to 
substantiate a diagnosis of CIDP. Moreover, all patients with CIDP received standard 
medical care and responded to treatment with intravenous immunoglobulin (IVIG), oral 
prednisone or plasma exchange (Table 3.2). 
3.3.2 Strength and Experimental Set-up  
All data were collected during one testing session with one control subject returning for a 
second visit to collect a sufficient number of action potential trains for firing rate 
measures. To record voluntary strength of the dorsiflexors, subjects were seated upright 
in a dynamometer (Cybex HUMAC NORM; CSMi Medical Solutions, Stoughton, MA) 
with the right leg fixed to an adaptor arm with the right ankle positioned at 30° of plantar 
flexion, while both knee and hip angles were maintained at 90°. Inelastic fastenings were 
wrapped over the dorsum of the foot to secure it to the dynamometer ensuring no aberrant 
movement. Control and patients with CIDP performed three to five dorsiflexion MVCs, 
with at least five min of rest between each attempt. All subjects were instructed to 
contract as hard and as fast as possible to ensure maximal rate of torque were achieved. 
Each MVC was held for three to five seconds. 
3.3.3 Electromyography 
Surface electromyography (sEMG) signals were recorded from the TA using self-
adhering Ag-AgCl electrodes (1 cm × 3 cm). The active electrode was positioned over 
the TA motor point, approximately seven cm distal to the tibial tuberosity and two cm 





sEMG signals were preamplified (×1,000), wide-band filtered between 10 Hz and 10 kHz 
(Neurolog, NL844; Digitimer), and sampled at 2 kHz (Power 1401; Cambridge 
Electronic Design). 
Intramuscular EMG signals were recorded during voluntary isometric contractions using 
two intramuscular tungsten electrodes 7,8,9. The electrodes were commercially available 
insulated tungsten needles (123 μm in diameter and 45 mm in length (FHC, Bowdoin, 
ME). After sterilization, these electrodes were inserted into the tibialis anterior muscle 
with one needle inserted distally in the TA muscle belly, and the other proximally (7-9 
cm distal to the patella).  The two intramuscular electrodes were connected to separate 
channels, and each needle was manipulated independently by an experienced operator. 
This allows the needle operator to sample at each contraction intensity from various 
discrete MUs, from different regions and depths of the muscle in order to build a 
representative MU profile. The intramuscular EMG signals were pre-amplified (×100) 
and wide-band filtered between 10 Hz and 10 kHz and sampled at 20 kHz per channel. 
The surface ground electrodes for the intramuscular recordings were positioned over the 
patella of the tested limb. Live visual and audio feedback of intramuscular EMG signals 
were provided to each operator independently. 
Multiple voluntary contractions were held for five to ten seconds at each of the three 
contraction levels (25%, 50%, 75%), whereas MVCs were held for three to five seconds. 
The order of contraction intensity was randomized.  MU action potential trains were only 
included when sampled during the steady-state torque plateau of each voluntary 
contraction (Figure 3.1). To sample from many different isolated MUs over the series of 





advanced slowly through the muscle in increments of ∼0.5 cm or less per voluntary 
contraction. Verbal encouragement was provided, and live visual feedback of force was 
displayed to each subject during all voluntary contractions. Fatigue was minimized by 
providing adequate rest (3-5 minutes) between contractions and the session ended when 
an MVC contraction was >5% lower than the baseline MVCs. 
3.3.4 Data Analysis and Statistics 
MU analyses were performed offline with Spike2 (Cambridge Electronic Design; 
Cambridge, UK) as described previously 8,9,10,11. To confirm spikes belonged to the same 
specific MU, each MU was first analyzed using a template shape algorithm, and then 
visually inspected by an experienced operator 7. To be accepted, rigorous inclusion 
criteria were applied and in addition to shape overlay of MU potentials a minimum of 
five consecutive contiguous action potentials (four inter-spike intervals) was required for 
each acceptable MU train. Additionally, a coefficient of variation of <30% for the inter-
spike intervals of each MU train was required for a train to be included in the analysis 12. 
Any doublet firings (>100 Hz) were not included in the MU analysis. An example of two 
discrete MU action potential trains extracted during an MVC from a control subject is 
provided  (Figure 3.1). It should be noted that the needle electrode was slowly advanced 
during each contraction and thus there are small variations in the amplitude and shape of 
the successive action potentials and inherent small temporal differences in the timing of 
each firing. However, the characteristic unique ‘signature’ of each firing was the critical 
feature used to determine a single train of action potentials arising from one MU and 
independent from other units. To statistically compare MU trains between controls and 





included units ranging from 12.5 - 37.5 % MVC, a 50% bin was from 37.5 % - 62.7%, a 
75% bin was from 62.5% - 85%, and 100% bin contained torque levels between 85% – 
100% of MVC 9. To assess surface EMG, 1.5 second time epochs were measured during 
the steady-state torque portion of all four voluntary contraction intensities. The 
electromyographic root-mean-square (EMG-RMS) amplitude during MVC torque was 
used to normalize surface EMG for the 25, 50 and 75% contraction intensities. To 
determine statistical significance between CIDP and controls Chi square calculations 
were performed on contraction bins to measure how expected outcomes compare to 
observed data.  
The R software program (version 3.6.1) was used for statistical analyses. Anthropometric 
data were compared using unpaired two-tailed t-tests. Pearson correlation coefficients 
were calculated for all mean MU firing rates dependent on MVC% for CIDP and control 
group. Random intercept mixed linear regression models were used to compare mean 
MU firing rates between control subjects and patients with CIDP for each voluntary 
contraction intensity bin using the lme4 package 13. To normalize data, mean MU firing 
rates were log-corrected, with null and full models with the subject as random effect 
estimates. The MVC%, MU train length, standard deviation of the firing rate means and 
the coefficient of variation of the mean firing rate were defined as fixed effect estimates. 
The models were a subset based on targeted contraction bins, with the Likelihood Ratio 







Mean age and anthropometric indices were not different between groups (Table 3.1). 
Patients with CIDP were 33% weaker for dorsiflexor MVC strength when compared with 
controls (Table 3.1). The intramuscular EMG sampling of voluntarily activated MUs 
yielded a total of 1389 MU action potential trains, with 664 from individuals with CIDP 
and 725 from control subjects (Figure 3.2). There are apparent differences in the scatter 
plots, depicting each MU firing rate as a discrete sample between control and CIDP 
groups (Figure 3.2). Although rates are higher in the CIDP group at the lower (25% 
MVC) contraction intensity compared to controls, the mean firing rates of binned units 
were not higher at intensities of 75 and 100% MVC. This resulted in a weak negative 
correlation with %MVC (r = -0.20 95% confidence interval = -0.27–-0.13, t = -5.37, p 
value = 1.08e-07) for the CIDP group. Results from the control group contrasted with the 
findings in the CIDP group, and showed a strong positive correlation between MU firing 
rate and MVC% (r = 0.78 95% confidence interval = 0.75-0.84, t =33.9, p value < 2.2e-
16).  
When mean MU firing rates were grouped based on target contraction intensities, 
histograms show the distributions of sampled MU firing rates grouped by contraction 
intensity up to MVC (Figure 3.3). Notably, very few MU firing rates occurred above 30 
Hz in the CIDP group. When the firing rate distributions at 75% and 100% of MVC were 
compared in the two groups, the rates in the CIDP group were significantly lower. At 
25% of MVC, the patients with CIDP demonstrated a higher MU firing rate range and a 
shifted distribution to higher MU firing rates. To test the effect of CIDP on MU firing 





bin (Figure 3.2). Both groups were equally capable of targeting the various MVC 
intensities (Table 3.3) and mean MU firing rates of patients with CIDP were higher at the 
lowest contraction intensity bin of 25% MVC (X2 = 15.9, df = 8, p value = 6.6e-05). 
Whereas, at the two highest contraction intensity bins, the firing rates in patients with 
CIDP were lower in comparison to controls (75 % of MVC; X2 =30.6, df = 8, p value = 
3e-08; 100% of MVC X2 = 42.2, df = 8, p value = 8.1e-11). There was no difference at 
50% of MVC between the control group and the patients with CIDP and this finding is 
further supported by the similarity between mean values (Table 3.3) and distribution 
ranges (Figure 3.3). Surface EMG (normalized to MVC) indicated that both groups had a 
positive linear relationship between contraction intensity bins and sEMG. However, 
sEMG was lower (P < 0.05) in patients with CIDP when compared with control subjects 












Table 3.1 Subject characteristics 
Anthropometric parameters Controls (n = 7) Patients with CIDP (n = 8) 
Men/Women 4/3 6/2 
Age (years) 58.0 ± 8.3 59.2 ± 6.5 
Height (cm) 152.0 ± 6.0 163.0 ± 4.0 
Mass (kg) 73.5 ± 9.4 79.4 ± 11.3 
BMI (kg/m2) 25.3 ± 2.8 27.8 ± 4.8 
Dorsiflexion MVC strength (Nm) 44.2 ± 4.8 29.8 ± 3.4* 





































M, 61 22 1/5 150   - 80g/ 4 weeks 
IVIG 
M, 63 6 4/5 75    20g/ 3 weeks 
IVIG 
M, 73 6 4/5 60    Plasma 
exchange/ 2 
weeks, 125 mg 
prednisone daily 
M, 68 3 4/5 70  - - 20g/ 2weeks IVIG 
M, 45 20 2/5 -    20 mg prednisone 
daily 
F, 59 10 5/5 290    5mg prednisone 
every other day 
M, 60 12 4/5 660    55g/ 4weeks IVIG 
F, 58 12 4/5 96    80g/3weeks IVIG, 
10mg prednisone 
daily 






Table 3.3 Motor unit data 
Values are means ± SD. MVC, maximal voluntary isometric contraction, ISI- interspike interval, EMG-
RMS- electromyography – root mean squared *P < 0.05 for interactions between control and CIDP  
 
Parameter CIDP    Control    
Targeted 
MVC % 
25 50 75 100 25 50 75 100 
MVC % 23.8 ± 3.8 46.8 ± 5.2 73.3 ± 5.5 94.3 ± 5.7 24.2 ± 5.4 47.2 ± 8.4 74.3 ± 6.6 96.2 ± 3.9 
Discharge 
rate Hz 
18.8 ± 1.1* 16 ± 6.3 18.1 ± 2.0* 17.1 ± 1.7* 13 ± 2.3 18.2 ± 4.4 31.6 ± 3.8 40.1 ± 2.3 
No. MU 
trains 
189 162 140 129 202 186 155 141 
No. of ISIs 
per MU train  




10.2 ± 4.1 12.4 ± 3.1 13.8 ± 2.6 15.2 ± 3.6 10 ± 3.5 11.1 ± 2.4 13.2 ± 3.9 14.1 ± 2.8 






Figure 3.1 Example of tungsten needle recording during a contraction 
A: Unprocessed tibialis anterior needle electromyography (EMG) recordings collected through tungsten 
electrodes from a healthy control subject.  B:  Examples of action potential shape and overlay of all action 
potentials from 2 identified motor unit (MU) trains. MU1 is an overlay of 9 action potentials with a 
coefficient of variation of 10.3, discharging at 21.8 Hz. MU2 is an overlay of 20 action potentials with a 
coefficient of variation of 8.8, discharging at 31 Hz. C: Raw torque tracing from a maximal voluntary 






 Figure 3.2 Scatter plot of MUFR 
Scatterplots of 1,389 individual motor unit action potential trains with 725 from the control subjects (A) 






Figure 3.3 Histograms of MUFR means 
Bars represent mean motor unit firing rates. Panel A is firing rates from a 25% contraction, B is 50%, C 
75% and D are firing rates from maximum voluntary contractions (100%).  Exact values are found in Table 
3.3.  
3.5 Discussion 
In this study we demonstrate that individuals with CIDP, in comparison to an age- and 
sex-matched healthy group, are 33% weaker in dorsiflexor strength and show distinct 
alterations in MU firing rates of the tibialis anterior from low to maximal intensity 
voluntary dorsiflexion contractions.  Patients with CIDP had significantly higher motor 
unit firing rates than controls at a low contraction intensity (25% MVC) and these MU 





MVC). Conversely, the control group showed increasing rate modulation as contraction 
intensity was increased, and at MVC the MU firing rates were approximately 55% higher 
than patients with CIDP. Both control subjects as well as patients with CIDP, had linear 
increases in surface EMG with increased voluntary isometric contractions. This finding is 
in agreement with the literature in that there is usually a positive or approximate linear 
relationship between torque and surface EMG 14. However, the patients with CIDP had 
significantly less normalized sEMG at 50 and 75% MVC compared with controls.  Thus, 
for force gradation from lower to higher contraction intensities patients with CIDP may 
rely more on recruitment than rate coding.  In conjunction, perhaps because patients with 
CIDP have an overall loss of MUs 2, the patients have fewer units to recruit and thus have 
lower sEMG specifically at the higher contraction intensities when recruitment of larger 
MUs normally is required. 
Our results are the first to investigate the firing characteristics of motor units in relation 
to a chronic peripheral demyelinating disease and may suggest that some degree of 
blocking of action potentials may be occurring along the axons, at the neuromuscular 
junction or potentially due to disruptions within the muscle fibers making the fibers 
unable to transmit high frequency (>30Hz) trains of action potentials.  Studies using 
animal models suggest that neuromuscular blocking in patients with CIDP could be due 
to a variety of factors including reduced axonal caliber, axon terminal dysfunction, ion 
channel alterations, structural changes in the muscle fiber and other possible mechanisms 
all related to chronic nerve demyelination 15,16. Any of these proposed alterations in 





propagation, velocity 17 and consequently affect MU firing rates of action potentials that 
do reach the muscle fibers. 
Muscle weakness is a cardinal feature of patients with CIDP, and in prior studies we 
reported that muscle quantity and quality are lower compared with control subjects and 
may account for much of the weakness 18,5. A component of lower skeletal muscle 
quantity and quality in patients with CIDP could be related to denervation and 
reinnervation from fewer numbers of MUs as shown previously 2.  Another study 
reported that when muscle from patients with CIDP was normalized to contractile cross-
sectional area, individuals with CIDP still demonstrated weakness compared to healthy 
controls 18. This indicates that despite accounting for non-contractile tissue from patients 
with CIDP, there remain inherent structural disruptions to the contracting proteins. Our 
results here indicate that lower firing rates in patients with CIDP at higher contraction 
intensities may also be a significant contributing factor to muscle weakness. 
Two studies of patients with CIDP, that used single fiber electromyography (SFEMG) in 
upper limb muscles reported abnormalities including increased fiber density and 
transmission instability compared with control subjects 15,16. Using stimulated SFEMG, it 
was determined that there was intermittent or persistent blocking in nerve fibers in the 
upper limb muscles of patients with CIDP 16. A study by Gilmore et al., (2017) 
investigated the number of MUs as well the stability of these MUs in individuals with 
CIDP in the tibialis anterior muscle.  That study demonstrated that individuals with CIDP 
had fewer motor units, with greater neuromuscular instability and motor unit discharge 
blocking in comparison to healthy aged and sex matched controls. As a consequence of 





alterations in neuromuscular transmission or decreased neuromuscular action potential 
propagation along the axon.  Moreover, increased MU firing rates are often observed 
during routine needle EMG studies performed by clinicians in patients with peripheral 
neuropathies, however contraction intensities rarely exceed 25% in this setting, which 
does not allow for the observation of failure of rate modulation at higher contraction 
intensities 19. 
In addition to differences in mean firing rates, at low levels of contraction, patients with 
CIDP did not have MU firing rates (MUFR) above 30Hz whereas rates greater than 40Hz 
were observed in control participants at 75% and 100% of MVC. These results 
demonstrate that MUs that would normally be active at high force levels are absent due to 
MU loss, or conversely these later recruited larger MU have a physiological propagation 
block or have undergone intrinsic changes in the motor neuron properties resulting in the 
inability to fire at these highest rates. 
Based on these observations it appears that force modulation beyond 25% MVC in 
patients with CIDP is mainly reliant on recruitment. However, these MUs that are later 
recruited may not have adequate firing rates to reach the necessary tetanic force.  
3.6 Conclusion 
These findings of altered motor unit firing rates and possible motor unit block in patients 
with CIDP may be fundamental in explaining some of the functional consequences 
related to weakness and atrophy. The inability of muscles to receive normal higher 
frequencies of excitation occurring over many years may have contributed to changes in 





CIDP patients.  Indeed, it is known that chronic low frequency muscle excitation will 
lead to dramatic detrimental changes on muscle properties 20,21. Perhaps if muscles in 
patients with CIDP, stop receiving rates of excitation beyond 30 Hz the muscle will 
respond and change its properties accordingly.  Importantly, studies examining 
microscopic muscle architecture in patients with CIDP would further elucidate the result 
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4 1Reductions In Muscle Quality And Quantity In CIDP 
Patients Assessed By Magnetic Resonance Imaging 
4.1 Introduction 
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an inflammatory 
peripheral nerve disorder with sensory disturbances and progressive muscle weakness in 
both the proximal and distal extremities. Most studies on neuroinflammatory diseases, 
such as multiple sclerosis and inflammatory myelopathies, have focused on the detection 
of specific neurological lesions using MRI 1,2. Indeed, nerve lesions in patients with 
CIDP have been shown by MR imaging in the lumbar nerve roots (L4 and L5), tibial 
nerve, and brachial plexus 3,4. In one study the lumbar nerve roots using MRI were 
evaluated in both treated and untreated CIDP patients and in those with polyneuropathy 
due to other etiologies.  They reported that MRI was useful in identifying nerve root 
hypertrophy, and as an adjunct test to identify CIDP in situations in which the diagnosis 
was uncertain 5. Furthermore, using another MRI technique Sinclair et al 6 demonstrated 
that magnetization transfer ratio (MTR) in the posterior leg muscles of patients with 
CIDP was significantly lower than controls, indicating that hydration changes or subtle 
biochemical disparities within the leg musculature had occurred in the chronic 
degenerative disease stage of CIDP.  
A version of this chapter has been published. Used with permission from John Wiley and Sons, Inc.  
1 
Gilmore K.J, Doherty, T.J, Kimpinski, K, Rice, C.L. Reductions In Muscle Quality And Quantity in CIDP 





Moreover, this study also established that lower MTR values in the anterior compartment 
of the leg correlated strongly with diminished ankle dorsiflexion strength. 
The loss of strength in muscles of those with CIDP is most severe distally, can be 
profound 7 and likely has a direct significance on functional impairments.  However, very 
little data exists regarding the limb musculature in persons with CIDP, specifically 
muscle quantity and quality.  A few studies have reported correlations between MRI 
detected nerve impairments and clinical findings (e.g., muscle strength and impairment) 
8,9.  Although force (strength) is strongly associated with the quantity of muscle tissue 
that is accessible for measurement, there are essential qualitative muscle properties 
involved that may also severely affect muscle strength 10.  Muscle quality can be defined 
as strength per unit of muscle mass as assessed by MR imaging methods, and is usually 
assessed by normalizing strength to cross-sectional area 11 or to total muscle volume 12,13. 
When muscle strength is normalized to tissue amount and strength deficits persist, this 
indicates deficiencies in contractile quality. Transverse magnetization (T2) relaxation 
time is a quantitative MRI sequence sensitive to small changes in proton density of a 
tissue. For example, when skeletal muscle atrophies with ageing or disease, a concurrent 
increase in non-contractile tissue, such as connective tissue and adipose tissue is 
deposited intramuscularly. Thus, in aging T2 relaxations times increase from 31ms in 
young adults to 42ms in those over 60 years 14. Increased T2 relaxation times therefore 
can reflect reduced contractile muscle tissue density contributing to muscle weakness 15. 
T2 weighted images and general anatomical MR scans are beneficial beyond calculating 
strength per unit mass, as they also provide a complementary understanding of tissue 





muscle weakness may be caused by reductions in both quantity and quality of skeletal 
muscle, but to date, no studies have investigated these features comprehensively. 
Additionally, an enhanced understanding of muscle structure and function in CIDP would 
be very helpful to compare to the well-known electrophysiological alterations in the 
peripheral nervous system of patients with CIDP 7.  To address this, we chose to focus on 
the dorsiflexor muscle group, specifically the tibialis anterior (TA), because of its distal 
limb location. The TA has important functional roles in gait and balance, and has been 
extensively studied in health, disease and aging, to provide comparative data 17,13,18. 
Accordingly, the purpose of the present study was to explore whether MRI is capable of 
detecting alterations in muscle quantity and quality relative to strength in those with 
CIDP when compared to a matched to a control group. 
4.2  Methods 
Subjects: Twelve patients (7 men, 5 women) with CIDP (mean age ∼61 years) and ten 
age- matched (mean age ∼60 years) control subjects (7 men, 3 women) were recruited to 
participate in this study. The local university research ethics board approved the study, 
and informed oral and written consent were obtained from both groups prior to testing.  
History, clinical, laboratory and electrophysiological features verifying a diagnosis of 
CIDP were obtained by an experienced neurologist, with specialty training in 
neuromuscular disorders and electrodiagnosis, to exclude other causes of nerve 
dysfunction (i.e. radiculopathies, other polyneuropathies, or compressive 
mononeuropathies). All patients with CIDP were diagnosed based on the criteria 
established by the European Federation of Neurological Societies (EFNS) 19. Patients 





related to CIDP) were not included in this study (Table 4.1). Standard measures of 
compound muscle action potential amplitudes (CMAP) nerve conduction velocities, and 
sensory nerve action potential amplitudes (SNAP) were compared to normative values to 
confirm a diagnosis. Furthermore, all patients with CIDP received usual medical care and 
responded to treatment with either plasma exchange, intravenous immunoglobulin 
(IVIG), or oral prednisone (Table 4.2). All control subjects were healthy, living 
independently and medication free. All control subjects were screened by a neurologist to 
eliminate any indication of neuromuscular disease.  
4.2.1 MRI Measures 
The MRI scans of the leg were acquired via serial axial plane scans in a 3.0-Tesla magnet 
(Magnetom Spectra 3T mMRBiograph; Siemens Healthcare, Erlangen, Germany). All 
MRI scans were completed during a single visit to the magnetic resonance imaging unit. 
Both CIDP and control subjects were inserted supine into the magnet feet first with the 
TA iso-centered to the bore of the magnet. Inelastic fastenings were used to secure firmly 
the legs and feet to the MR table to prevent subtle movements throughout the scanning 
procedure. The complete musculature of the left and right legs was imaged from the level 
of the tibial plateau to the distal malleoli. MRI for anatomical measures were acquired by 
means of a 3D FLASH sequence with the following parameters: 9.57-ms repetition time 
(TR); 2.46-ms echo time (TE); 320 x 240 matrix; 243 x 325-mm field of view; 384 slices; 
and 0.9mm slice thickness, with slice separation of 1 mm. Total scan acquisition time for 
the anatomical scan was approximately 13 min per subject. In a secondary scan during 
the same session, T2 relaxation time was determined by means of a spin–echo sequence 





subsequent echoes with 16 equidistant steps had an increment of ΔTE =13.2 ms between 
13.2 and 211.2 ms. Other parameters were: slice thickness = 5 mm; matrix = 128 x 128; 
field of view = 325 x 325; slices = 30; bandwidth = 601 HZ/Pixel. Total scan acquisition 
time for T2 was approximately 12 min per subject.  
4.2.2 TA Total Volume, Muscle Composition, and T2 Relaxation 
Times  
Manual and semi-automated image analysis procedures were used offline to measure 
total TA muscle areas, volumes, composition (contractile versus non- contractile muscle 
tissue), and T2 relaxation times by means of imaging processing software (OsiriX version 
8.2). The researcher was blinded to the group allocation of each subject. Total TA muscle 
volume was calculated by manually delineating regions of interest (ROIs) around the 
most proximal portion of the TA and at every third slice (2.6 mm) to the most distal slice 
comprising distinguishable muscle tissue. Connective tissue, blood vessels, and adipose 
tissue were eliminated during the manual tracing of the TA. Subsequently, all ROIs 
within the series were saved for further analysis of non-contractile tissue volume. In order 
to calculate TA non-contractile tissue volume, an ROI was created, indicative of muscle 
tissue only. We used the same method as Moore et al. 10 for non-contractile tissue 
volume. T2 relaxation time was calculated for each slice of the TA and a mean T2 
relaxation time was calculated for each individual subject. TA ROIs were manually 
traced using the same method as described above in the anatomical scans. Pixel-by-pixel 
parametric color maps (magma) of T2 relaxation times were created from the signal 
intensity of 16 echo images of the TA. The T2 relaxation time was then calculated by 





tissue identified was subtracted from the total TA volume to achieve a volume of 
contractile tissue only. In addition, this fat corrected volume was used to normalize the 
MVC strength (strength per amount of contractile tissue). 
4.2.3 Strength Assessment  
On a separate appointment that occurred within 1-3 weeks of the MRI tests, voluntary 
strength and activation of the dorsiflexors were measured.  Subjects were seated in a 
custom isometric dorsiflexion dynamometer 20 with the left ankle positioned at 30° of 
plantar flexion, while both knee and hip angles were maintained at 90°.  Inelastic straps 
were wrapped over the dorsum of the foot to secure the foot to the dynamometer. 
Movement at the hip was disparaged by securing a padded, C-shaped brace to the distal 
aspect of the left thigh. 21,16. Subjects performed three dorsiflexion MVCs, with at least 3 
min of rest between each attempt. Subjects were instructed to contract as hard and as fast 
as possible to ensure maximal torque, and rate of torque development, was achieved. 
Each MVC was held for approximately 3–4 s. Voluntary activation during the 2nd and 
3rd MVC attempts was assessed using the interpolated twitch technique 22. All torque 
signals were collected and sampled online at 500 Hz using Spike2 software (Version 
7.11; Cambridge Electronic Design, Cambridge, UK) and analyzed off-line to determine 
voluntary isometric torques (strength). Compound muscle action potential responses of 
the TA were obtained by supramaximal, percutaneous electrical stimulation of the fibular 
nerve, distal and posterior to the fibular head. Stimulation was performed through a bar 
stimulating electrode using single, 100- us square-wave pulses via a constant-voltage 







Statistical analysis was performed using SPSS software (version 22). Normally 
distributed data were analyzed using an independent-samples t-test. The Levene test was 
used to determine homogeneity of variance. Non-normal distributions were assessed 
using the Shapiro–Wilk test of normality. The T2 relaxation times were not normally 
distributed and were assessed using Mann–Whitney non-parametric t-tests. The results 
were considered significant at P ≤ 0.05. All data are presented as mean ± standard 
deviation. 
4.3 Results 
There were no significant differences in age, height, weight and BMI between the 
patients and control subjects.  Participant characteristics are presented in Table 4.1 and 
the clinical features of the patients with CIDP are listed in Table 4.2. Despite similar and 
equal high levels of voluntary activation (>95%), isometric strength when compared with 
controls was significantly lower in the subjects with CIDP (Table 4.3). Patients also had a 
lower compound muscle action potential (CMAP) amplitude compared to controls (Table 
4.3). When normalized to total muscle volume, patients with CIDP strength was 
approximately 29% lower than controls (Table 4.3), and when normalized to fat corrected 
contractile tissue volume, CIDP strength was approximately 18% lower compared with 
controls. Overall, TA muscle volumes of patients with CIDP were significantly reduced 
compared to controls. As a relative percentage of total muscle volume, patients had 
significantly less contractile tissue compared with controls (Table 4.3). Consequently, 
non-contractile tissue quantities were significantly greater in CIDP when compared with 





abundant in patients with CIDP when compared with controls (Figure 4.1).  Furthermore, 
as shown in Figure 4.2, T2 relaxation times were ~39% longer in duration in CIDP versus 
controls. Figure 4.3 shows the T2 map of the TA in a patient with CIDP compared with a 
control subject.  
Table 4.1 Participant characteristics 
Anthropometric parameters Controls (n = 10) Patients with CIDP (n = 12) 
Men/Women 7/3 7/5 
Age (years) 59 ± 7.6 60.8 ± 9.1 
Height (cm) 167.0 ± 5.0 169.0 ± 8.0 
Mass (kg) 71.5 ± 10.3 80.5 ± 10.1 
BMI (kg/m2) 26.2 ± 3.1 27.5 ± 4.1 


































 M, 77 8 4/5 330    75g/ 3weeks 
IVIG 
 M, 61 22 1/5 150   _ 80g/ 4 weeks 
IVIG 
 F, 62 6 4/5 75    20g/ 3 weeks 
IVIG 
 M, 73 6 4/5 60    Plasma 
exchange/ 2 
weeks, 125 mg 
prednisone 
daily 
 M, 47 5 5/5 85   _ 55g/ 3 weeks 
IVIG 
 M, 68 3 4/5 70  _ _ 20g/ 2weeks 
IVIG 







 F, 59 10 5/5 290    5mg 
prednisone 
every other day 
M, 60 12 4/5 660    55g/ 4weeks 
IVIG 




F, 59 4 5/5 64  _ _ 60g/2 weeks 
IVIG 
F, 58 9 5/5 125   _ 30g/2weeks 
IVIG 














Table 4.3 Strength, electrophysiology, and imaging parameters. 
 
MVC- maximum voluntary contraction, CMAP- compound muscle action potential, Neg PK - negative 
peak amplitude; N·m- Newton meters. *Significantly different than control (P < 0.05). Values are expressed 
as mean ± standard deviation. 
Parameters Controls 
(n = 10) 
Patients with CIDP 
(n = 12) 
Difference 
MVC strength (Nm) 42.1 ± 3.2 26.8 ± 3.5* -36.3 % 
TA CMAP Neg PK amplitude 
(mV) 
7.1 ± 0.9 4.3 ± 0.8* -39.4 % 
Voluntary activation (%) 98 95 3% 
Total muscle volume (cm3) 117.3 ± 25.2 97.8 ± 17.3* -17.5 % 
Total contractile TA volume (cm3) 110.2 ± 23.5 81.3 ± 15.7* -26.2 % 
Contractile volume (%) 93.2 ± 3.8 84 ± 2.2 -9.8 % 
Non-contractile volume (%) 6.8 ± 2.2 16 ± 5.2* 58.2 % 
MVC/total muscle volume 
(N·m/cm3) 










Figure 4.1 MRI cross section of left leg 
MRI general anatomic scan: comparison of leg muscles of CIDP (left) vs. control (right) in 2 male 
participants. The patient with CIDP is 54 years old and the control subject is 55 years old. The TA muscle 
is outlined in green. Note the extensive intramuscular fat infiltration in the patient with CIDP throughout 
the leg. 
 
Figure 4.2 T2 relaxation times  
T2 relaxation times of the tibialis anterior. *Significantly longer than control (P < 0.05). Values are 







Figure 4.3 T2 maps 
T2 maps (ms) of the tibialis anterior muscle: CIDP (left panel) and control (right panel). Purple: muscle 
(30–70 ms); orange to yellow: fat (>71 ms); black and blue: connective tissue (<30 ms). T2 maps displayed 
here are for the same participants as those depicted in Figure 4.1.  
4.4 Discussion 
Using two MRI based techniques (T1 and T2 weighted scans) we have revealed 
quantitative and qualitative changes in muscle, indicating that compared with control 
subjects those with CIDP have structural alterations affecting the contractile capacity of 
muscle tissue. The most salient findings from this study are that patients with CIDP had 
lower total muscle protein quality and more non-contractile tissue infiltration in the TA, 
as indicated both by a greater amount of non-contractile tissue and elongated T2 
relaxation times when compared to control subjects. Furthermore, CIDP muscles had 
lower normalized strength values than controls when related to corrected muscle 
volumes.  Absolute dorsiflexion strength of patients with CIDP was ~36% less than the 
control subjects. This was not due to differences in voluntary activation of the 





was expressed relative to strength (normalized strength), the difference between groups 
persisted at ~29% lower normalized strength for the CIDP group compared with controls. 
This difference denotes a large difference in muscle contractile quality between CIDP 
and control subjects indicating that weakness is not simply due to frank loss of tissue. 
This is further reinforced by the ~39% longer T2 relaxation times in the CIDP group 
when compared with controls. Consequently, beyond validating dorsiflexor muscle 
weakness in CIDP, our findings indicate a decrease in protein quality and a loss of total 
muscle tissue density in the TA of patients with CIDP. Our findings support and extend 
those of Sinclair et al (2012) who found that MTR in the calf muscles was significantly 
lower than controls in a group of patients with CIDP 6.  
CMAP amplitude, which provides an indication of excitable muscle mass was ~40 
percent lower in the CIDP patient group. This finding aligns with our MRI results, which 
showed that CIDP patients had a smaller TA volume when compared to controls. Disease 
duration did not correlate with the amount of skeletal muscle loss in patients with CIDP. 
The muscle weakness in the patients, at the whole-muscle level, could be due to a 
quantitative loss of muscle due to denervation or impaired nerve innervation associated 
with CIDP, thus allowing replacement of functional muscle tissue with non-contractile 
tissues (adipose tissue). Indeed, it has been reported that dorsiflexion muscle weakness 
observed in patients with a peripheral neuropathy is correlated with proliferations in 
intramuscular adipose tissue, determined from T1-weighted MRI scans 20,23. This 
indication has been further confirmed in our study by longer T2 relaxation times found 
for the patients with CIDP when compared to the T2 relaxation times of the control 





30 and 70ms 24, and the control subjects in our study showed a mean value of 59ms. 
Conversely, the T2 relaxation times of the patients with CIDP were 79ms, which was 
significantly longer than the controls.  Longer T2 relaxation times are indicative of tissue 
that is less dense (lipid in structure) due in part to the slower motion of protons both in 
macromolecules as well as water molecules attracted to the surface of the macromolecule 
24. 
Heterogeneous expansion of intramuscular non-contractile tissue and fatty infiltration 23 
may not only reduce total muscle mass, but also could disrupt normal fascicular 
organization. Consequently, unfavorable changes in muscle tissue composition are likely 
key structural alterations that contribute to muscle weakness in CIDP. Findings from 
other MRI studies that assessed cross sectional area of peripheral nerves including L5 and 
cauda equina diameter, indicate that innervated muscle tissue would be affected 2. Our 
findings are also supported by a study that found muscle disruptions in Charcot-Marie-
Tooth neuropathy 25 and in another that showed declines in skeletal muscle function in 
patients with diabetic peripheral neuropathy 26. Thus, reductions in muscle quantity and 
quality are likely driven by CIDP-related neural factors, such as motor axon loss 7 and 
impaired neural signaling perhaps related to nerve lesions as reported in prior studies that 
presumably lead to accelerated muscle atrophy 3.  
Importantly, we found that patients with CIDP were weaker relative to volume of muscle 
even when compared using fat corrected muscle volumes (normalized force). This 
indicates that the intrinsic force generating capacity of the presumed viable muscle tissue 
is lower in those with CIDP than controls supporting the concept that disruptions in 





with CIDP have impaired neuromuscular stability (higher jitter and jiggle) and percent 
blocking compared to controls 7. These nerve alterations therefore could lead to 
diminishments in muscle strength even when corrected for non-contractile tissue. 
Although motor unit or axon loss is a feature of CIDP 7 it is not known whether there is a 
preferential loss of for example Type II fibers and via collateral reinnervation of 
remaining Type I fibers found in ageing 26 and other neuropathies contributing to 
morphological changes within the muscle. Ultimately, due to a poorer quality of 
reinnervation, these muscle fibers may have intrinsic strength decrements as 
demonstrated in the present study by lower contractile force per cross sectional area 
(volume) 27,28. 
In using MRI sequences, T2 and the general anatomical scans, important insights have 
been gained into fundamental changes of skeletal muscle in patients with CIDP. 
Dorsiflexor weakness in CIDP is likely an outcome of numerous factors, including, but 
not limited to motor unit loss and accompanying muscle denervation and atrophy. 
Impaired neural signaling due to the primary site of lesions of the peripheral nerves also 
may indirectly contribute to poorer muscle tissue quality as reflected by lower normalized 
force compared with controls. Accordingly, T2 and the general anatomical scans can 
offer additional understanding into pathological and morphological disruptions to whole-
muscle tissue composition that may contribute to diminished muscle function in CIDP. 
These results further support the utilization of MRI as a tool for muscle analysis and 
provide a better understanding of the impact of neuronal changes in CIDP on muscular 
characteristics. Finally, this information may be essential in targeting and evaluating 
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5  1Nerve Dysfunction Leads To Muscle Morphological 
Abnormalities In Chronic Inflammatory Demyelinating 
Polyneuropathy Assessed By MRI  
5.1 Introduction  
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease 
characterized primarily by demyelination and secondary axonal degeneration of 
peripheral nerves. Patients typically present with symmetrical motor deficits such as 
diffuse muscle weakness, as well as sensory impairments. Focal alterations in the 
lamellar pattern of myelin, which lead to segmental demyelination, are present in CIDP. 
The myelin sheath becomes discontinuous which has repercussions in relation to axonal 
conductance 1. Studies related to neuromuscular function have mainly focused on the 
neuropathic aspects of CIDP and their involvement in motor impairment. However, 
changes in skeletal muscle quality and quantity maybe a consequence of motor nerve 
deficits, but these aspects have not been investigated extensively 2,3. Nerve lesions in 
CIDP have been shown by magnetic resonance imaging in the lumbar nerve roots (L4 
and L5), tibial nerve, and brachial plexus 4,5. To date, the effect of nerve lesions in 
patients with CIDP has not been comprehensively explored in relation to quality and 
quantity of skeletal muscle. Only a few studies have describe dissociations between  
A version of this chapter has been published. Used with permission from John Wiley and Sons, Inc.  
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Gilmore K.J, Fanous J, Doherty, T.J., Kimpinski, K., Rice, C.L. Nerve Dysfunction Leads To Muscle 
Morphological Abnormalities In Chronic Inflammatory Demyelinating Poloyneuropathy Assessed By MRI 





MRI detected nerve impairments and clinical findings of decrements in muscle strength 
6,7. T2-weighted MRI and general anatomical MRI (T1) are advantageous beyond 
providing an overall assessment of muscle mass that can be used for example to 
normalize strength measures, as they also provide a complementary understanding of 
tissue density and muscle protein structural integrity 8,9. Thus, muscle weakness in 
patients with CIDP may be related to reductions in both quantity and quality of skeletal 
muscle, however only one study has investigated muscle morphology in patients with 
CIDP 10.  
A previous study from our group found that overall tibialis anterior (TA) muscle volumes 
were lower in patients with CIDP compared with age and sex matched controls, and 
dorsiflexion strength was approximately 29% lower in the CIDP group 10. Furthermore, 
non-contractile tissue quantities were roughly 60% greater in the TA muscle of patients 
when compared with controls. Thus, when strength was normalized to fat corrected 
contractile tissue volume, strength remained lower by approximately 18% in patients with 
CIDP compared with controls 10. Although the dorsiflexors have functional importance in 
gait and balance, it remains to be determined whether these findings are unique to this 
muscle group for anatomical and functional reasons or whether other muscles of the leg 
would be affected similarly. Moreover, because CIDP affects distal musculature more 
severely 11 we investigated the triceps surae, including the soleus, medial head of 
gastrocnemius (MG), and lateral head of gastrocnemius (LG). Indeed, the triceps surae 
has important functional roles in gait and balance, and has been extensively studied in 





Histochemical studies have shown that the TA contains 70–75% type II fibers 15 and 
similarly the soleus, is rather homogeneous, being composed of 80% type I muscle fibers 
14,15. However, unlike the TA, the soleus muscle has been shown to be spared from age-
related muscle atrophy, contractile slowing, and a loss of motor units when compared to 
the TA 16. Furthermore, when the soleus is compared with the gastrocnemii, which are 
composed of about 50% slow twitch (ST) fibers, the gastrocnemii show substantial 
anatomical loss when older individuals are compared with younger adults 17. Thus, there 
may be anatomical or functional features among different muscles despite sharing the 
same spinal nerve root innervation that could be affected differently by the demyelination 
process of peripheral nerves. Given these deficiencies in the literature, a more 
comprehensive understanding of muscle structure and function from various muscle 
groups in CIDP would be advantageous in addition to the well-known 
electrophysiological and anatomical alterations in the demyelinated peripheral nerves of 
CIDP patients 10. Accordingly, the purpose of the present study was to explore the large 
muscles of the posterior leg compartment to examine the degree to which plantar flexion 
strength and muscle quantity and quality are affected in those with CIDP when compared 
to matched controls. It was hypothesized that demyelinated peripheral nerves would lead 
to uniform reduction in all portions of the triceps surae in both quantity and quality of 
muscle of patients with CIDP. 
5.2 Methods 
Ten patients (six men, four women) with CIDP (mean age 62 years) and nine age- 
matched (mean age 60 years) control subjects (five men, four women) participated in this 





groups provided informed oral and written consent prior to testing. A clinical history, as 
well as laboratory and electrophysiological descriptions verifying a CIDP diagnosis were 
obtained by an experienced neurologist, with specialty training in electrodiagnosis and 
neuromuscular disorders. All other causes of nerve dysfunction (i.e.,radiculopathies, 
other polyneuropathies, or compressive mononeuropathies) as well patients with any 
metabolic (including diabetes), neurological, or vascular diseases (other than related to 
CIDP) were screened and these subjects were not included in this study. All patients were 
diagnosed based on the criteria established by the European Federation of Neurological 
Societies 11 (Table 5.2). Standard measures of nerve conduction velocities, compound 
muscle action potential amplitudes (CMAP) (Table 5.1) and sensory nerve action 
potential amplitudes (SNAP) were compared to normative values to establish a CIDP 
diagnosis. Furthermore, all patients with CIDP were receiving usual medical care and 
responded to treatment with intravenous immunoglobulin (IVIG), oral prednisone, or 
plasma exchange (Table 5.2). All control subjects were healthy, medication free, living 
independently and were screened by the same neurologist to eliminate any indication of 
neuromuscular or metabolic disease. 
5.2.1 Strength Assessment  
Within the same week as the MRI scans were acquired, voluntary strength of the right 
plantar flexors was measured. For strength assessments, subjects were seated in a plantar 
flexion isometric dynamometer with the right ankle positioned at 90°of plantar flexion 
and both knee and hip angles were maintained at 90°18. Movement at the hip was 
minimized by fixing a thinly padded, C-shaped sup-port over the distal aspect of the right 





the dorsum of the foot and the toes to secure the foot to the dynamometer footplate. 
Control subjects performed three plantar flexion maximum voluntary isometric 
contractions (MVCs), with 3–5 min of rest between each contraction. Patients with CIDP 
required three to five maximal isometric contractions, with two or more contractions of 
the contractions within 5% of each other. To mitigate fatigue in the group 5 min of rest 
was given between each maximal contraction. Both groups were given strong verbal 
encouragement and torque visual feedback. Each MVC was held for approximately three 
to four seconds. MVC torque was calculated as the highest torque value achieved from 
any of the three attempts. All torque signals were collected and sampled online at 500 Hz 
using Spike2 software (Version 7.11; Cam-bridge Electronic Design, Cambridge, UK) 
and analyzed offline to determine voluntary isometric torques (strength). 
5.2.2 MRI Measures 
 All MRI scans were completed during a single visit to the MRI unit. Scans of the triceps 
surae were acquired via serial axial plane images in a 3.0-Tesla magnet (Magnetom 
Spectra 3T mMRBiograph; Siemens Healthcare, Erlangen, Germany). Control and CIDP 
subjects were inserted supine into the magnet, feet first with the triceps surae iso-centered 
to the bore of the magnet. Inelastic fasteners were used to secure tightly the legs and feet 
to the MR table to avoid subtle movements during the scanning process. The complete 
musculature of the left and right legs was imaged from the distal malleoli to the proximal 
tibial plateau. MRI for anatomical measures (T1) were acquired by means of a 3D 
FLASH sequence with the following parameters: 9.57-ms repetition time (TR); 2.46-ms 
echo time (TE); 320×240 matrix; 243×325-mm field of view; 384 slices; and 0.9 mm 





anatomical scan was approximately 13 min per subject. A secondary scan during the 
same session was performed to determine T2 relaxation times by means of a spin–echo 
sequence with a TR of 3,500 ms. The first spin–echo was acquired at TE =13.2 ms; the 
subsequent echoes with 16 equal distant steps had an increment of ΔTE =13.2 ms 
between 13.2 and 211.2 ms. Other parameters were: slice thickness = 5 mm; matrix = 
128×128; field of view = 325×325; slices = 30; bandwidth = 601 Hz/pixel. Total T2 scan 
acquisition time was approximately 12 min per subject. 
5.2.3 Triceps Surae Total Volume, Muscle Composition, and T2 
Relaxation Times  
Before calculating MRI results, an inter- rater reliability test was completed to evaluate 
the reliability of two experimenters calculating muscle mass and subsequently 
quantifying contractile versus non-contractile tissues in the triceps surae complex. The 
results of this test indicated that both evaluators were within 95% confidence with each 
other. Manual and semi-automated image analysis procedures were used offline to 
measure the soleus, medial and lateral gastrocnemii muscle areas, volumes, composition 
(contractile versus non contractile muscle tissue), and T2 relaxation times by imaging 
processing software (OsiriX version 8.3). The researcher was single blinded to group 
allocation. Total soleus, medial and lateral heads of gastrocnemius muscle volumes were 
calculated by independently manually delineating regions of interest (ROIs) around the 
most proximal portion of each muscle and at every third consecutive slice (2.6 mm) to the 
most distal slice containing distinguishable muscle tissue. Connective tissue, adipose 
tissue and blood vessels were eliminated during the manual tracing of each of the three 





analysis and calculation of non-contractile tissue volumes. In order to calculate non-
contractile tissue volumes for all three muscles an ROI was created, indicative of only 
muscle tissue 20. T2 relaxation time was calculated for each slice of the soleus, medial 
and lateral heads of gastrocnemius and a mean T2 relaxation time was calculated for each 
subject. The soleus, medial and lateral heads of gastrocnemius muscle ROIs were 
manually traced using the same method as described above in the (T1) anatomical scans. 
Pixel-by-pixel parametric color maps (magma) of T2 relaxation times were created from 
the signal intensity of 16 echo images of the three muscles. The T2 relaxation time was 
then calculated by means of the T2 Fit Map plug-in (version 1.5). The total amount of fat 
and non-contractile tissue identified was subtracted from the total volume of each muscle 
compartment to achieve a volume of contractile tissue only. In addition, this fat corrected 
volume was used to normalize the MVC strength (strength per amount of contractile 
tissue). 
5.2.4 Statistics  
Statistical analysis was performed using SPSS software (version 22). Normally 
distributed data were analyzed using an independent-samples t-test. The Levene test was 
used to determine homogeneity of variance. Non-normal distributions were assessed 
using the Shapiro–Wilk test of normality. The T2 relaxation times that were not normally 
distributed were assessed using Mann–Whitney non-parametric t-tests. Cohen’s D effect 
sizes were calculated for group differences. The results were considered significant at 






There were no significant differences in age, height and weight between the patients with 
CIDP and control subjects. Participant characteristics are presented in Table 5.1 and the 
clinical features of the patients are listed in Table 5.2. Isometric plantar flexion strength 
was 28% lower in patients with CIDP when compared with controls (Table 5.1). 
Electrophysiological findings also indicated axonal dysfunction with patients having 50% 
lower CMAP amplitude of the tibial nerve compared to controls (Table 5.1). The total 
triceps surae volume of patients with CIDP was significantly lower by 19.3% compared 
to healthy controls. When eliminating the fat and other non-contractile tissue within the 
total volume of the triceps surae, the patients with CIDP had 47.5% less contractile tissue 
(Figure 5.1). Consequently, non-contractile tissue quantities were significantly greater 
(82%) in CIDP when compared with controls (Figure 5.2). Qualitatively, subcutaneous 
fat was more abundant in patients with CIDP when compared with controls. When 
normalized to total triceps surae muscle volume, strength was approximately 17% lower 
in CIDP than controls (Table 5.1) and when normalized to fat corrected contractile tissue 
volume, CIDP strength was approximately 30% lower compared with controls. 
Furthermore, as shown in Figure 5.3, T2 relaxation times in the soleus, medial and lateral 
heads of gastrocnemius were 36.8%, 37.3% and 26.0% longer induration (although not 
statistically significant) in CIDP versus controls. Figure 5.4 shows cross-sectional T1-
weighted MRI scan comparing leg musculature of control versus CIDP with the soleus 
(SL), MG and LG outlined. Figure 5.5 shows the T2 map of the triceps surae (SL in blue, 






Table 5.1 Participant characteristics   
Subject characteristics Controls (n = 9) Patients with CIDP (n = 10) 
Men/Women 5/4 6/4 
Age (years) 59 ± 6.2 61.8 ± 8.2 
Height (cm) 167.0 ± 3.0 169.0 ± 8.0 
Mass (kg) 73.5 ± 9.4 80.5 ± 8.4 
MVC strength (Nm) 132.7 ± 12.2 95.3 ± 8.8* 
Normalized strength to total triceps 
surae volume (Nm/cm3) 
0.24 ± 0.03 0.15 ± 0.01* 
CMAP (mV) 7.5 ± 0.34 3.7 ± 0.72* 
 
MVC - maximum voluntary contraction; CMAP - compound muscle action potential of tibial nerve. There 
were only significant differences (P< 0.05) in strength. Normalized strength is expressed as fat corrected 































M, 77 8 3/5 3.3    75g/ 3weeks 
IVIG 
M, 61 22 1/5 1.5   - 80g/ 4 weeks 
IVIG 
F, 62 6 4/5 0.75    20g/ 3 weeks 
IVIG 
M, 73 6 4/5 0.6    Plasma 
exchange/ 2 
weeks, 125 mg 
prednisone daily 
F, 60 7 4/5 0.75   - 45g/ 3 weeks 
IVIG 
M, 63 3 4/5 0.7  - - 20g/ 2weeks 
IVIG 
M, 45 20 2/5 -    20 mg 
prednisone daily 
F, 59 10 5/5 2.9    5mg prednisone 





M, 60 12 4/5 6.6    55g/ 4weeks 
IVIG 




CSF- Cerebral spinal fluid; IVIG- Intravenous immunoglobulin; - represents no value;  - value observed; 
CB-Conduction block; TD - Temporal dispersion, M-Male, F-Female 
 
Figure 5.1 Total muscle volume of triceps surae 
Total muscle volumes of the soleus, medial head of gastrocnemius (MG), and lateral head of gastrocnemius 































Figure 5.2 Total contractile volume triceps surae 
Total triceps surae contractile volumes of the soleus, medial head of gastrocnemius (MG), and lateral head 
































Figure 5.3 T2 relaxation times of triceps surae  
T2 relaxation times of the soleus, medial head of gastrocnemius (MG), and lateral head of gastrocnemius 




































Figure 5.4 MRI T1 cross section of triceps surae 
Cross-sectional T1-weighted MRI scan: comparing leg musculature of control (left) vs. CIDP (right). 
Soleus (SL), medial head of gastrocnemius (MG) and lateral head of gastrocnemius (LG) are outlined. Note 
the prominent marbleized appearance of the leg muscles of the patient with CIDP due to extensive 
intramuscular fat infiltration. 
 
Figure 5.5 MRI T2 cross section of triceps surae 
T2 maps (ms) of the soleus (SL), medial head of gastrocnemius (MG), and lateral head of gastrocnemius 
(LG) muscles: control (left panel) vs. CIDP (right panel). Muscle: purple, blue (30-70ms); fat green, yellow 
(>71 ms); connective tissue: black, purple (<30 ms). T2 ranges values from 21. T2 maps displayed here are 






 The present study aimed to establish the degree to which the posterior leg compartment, 
specifically the triceps surae is affected by the demyelinating nerve disease CIDP. 
Utilizing two MRI techniques, (T1 andT2-weighted scans), we discovered quantitative 
structural alterations in all portions of the triceps surae, demonstrating that patients with 
CIDP have significant atrophy and no contractile tissue infiltration that severely affect the 
contractile capacity of skeletal muscle tissue. Absolute plantar flexion strength of patients 
was roughly 28% less than the control subjects and when triceps surae muscle volume 
was expressed relative to strength (normalized strength), the difference between groups 
persisted with roughly 30% lower normalized strength for the CIDP group when 
compared to controls. The persistence of the strength difference is indicative of the lower 
muscle contractile quality in CIDP, which is further supported by the roughly 35% longer 
T2 relaxation times in all three muscles of CIDP individuals compared with controls. 
Thus, muscle weakness in patients with CIDP cannot be due to a loss of muscle tissue 
alone. Furthermore, disease duration was not related to the amount of skeletal muscle 
mass present in patients. Electrophysiological outcomes also indicated more prominent 
abnormalities that were suggestive of axonal dysfunction (e.g., CMAP amplitude) in the 
lower extremity. T2 relaxometry and water-fat separation techniques were not used in 
this study, thus we are notable to quantify total fat infiltration separated from water 
content or other non-contracting substances. The most important conclusions from this 
study are that patients with CIDP had significantly less total muscle volume indicated by 
T1 scans, as well lower total muscle protein quality as reflected by longer T2 relaxation 





lateral heads of gastrocnemius and supported by longer T2 relaxation times when 
compared to control subjects. It is important to draw attention to the two possible 
contributing mechanisms at play in the patients. Not only are these patients 
disadvantaged by chronic nerve demyelination, but also the process of aging may 
compound these effects. Several studies using MRI techniques that have compared age-
associated differences in muscle composition have shown that various muscles within the 
leg are affected to different degrees by aging. One study demonstrated that triceps surae 
muscle volume could be reliably calculated using maximal anatomical cross-sectional 
area values from MRI scans 22. A subsequent study investigated changes in the 
architecture of the triceps surae muscle architecture in a group of young men (25.3 ± 4.5) 
and a group of old men (73.8 ± 4.4). Additionally, that study reported that the triceps 
surae in the old group was smaller in volume in all individuals compared with the young 
17. Our mean values for the control subjects fit closely with the volumes presented by this 
group. Furthermore, a study showed age-associated reductions in contractile tissue and 
subsequent increases in adipose and connective tissue composition using MRI in the 
triceps surae. These results further support our control group findings regarding force as 
well as muscle volume. In the older cohort, in addition to 39% lower isometric plantar 
flexion strength, total triceps surae volume was smaller by 17.5%, whereas the relative 
amounts of triceps surae intramuscular adipose tissue and gastrocnemii intramuscular 
connective tissue were larger by 55.1%and 48.9%, respectively 23.  
A study by Dalton et al (2009) supports that not all skeletal muscles are affected equally 
by the aging process and that the soleus in relation to both heads of the gastrocnemius 





aged individuals 24. Indeed, it has been shown that sarcopenia is much more apparent in 
the LG and MG compared with soleus 17. Heterogeneous increases of intramuscular 
adipose and non-contractile connective tissue may not only diminish total triceps surae 
muscle mass, but also could alter the usual fascicular fibre organization 25. This may help 
explain the lower specific tension we found for this muscle group. Consequently, 
negative changes in skeletal muscle tissue amount and relative composition of contractile 
verses no contractile tissue lead to important structural modifications that contribute to 
plantar flexion muscle weakness in patients with CIDP. Thus, although disuse and age-
related factors may play a role in the observed differences, it is likely that the primary 
cause is axonal dysfunction. In the past decade, numerous abnormal MRI findings in 
nerves of patients with CIDP have been reported.  
Several studies have discovered abnormal hypertrophy of both ventral and dorsal spinal 
nerve roots in CIDP 26,27,28,29,30,31 which has also been demonstrated in Guillain–Barre 
syndrome 32,33. Hypertrophy of spinal nerve roots has frequently been described in 
combination with abnormal nerve enhancement 34,35,36. Increased signal intensity on T2-
weighted images in the brachial plexus or nerve trunks has also been observed in some 
CIDP MRI studies 37,38,39. Although nerve root enlargement is not specific for CIDP, 
several studies have demonstrated the frequencies of these abnormalities that are detected 
by MRI. For example, Midroni et al (1999) reported enhancement of the cauda equina in 
(69%) of patients with CIDP 28 and Duggins et al (1999) reported detection of cervical 
nerve root hypertrophy in (57%) of patients with CIDP 27. Although these structural nerve 
abnormalities are apparent, few studies have explored the effect on skeletal muscles. In a 





Charcot–Marie-Tooth neuropathy 40 and some that have shown declines in skeletal 
muscle quantity and quality in patients with diabetic peripheral neuropathy 17, 41. Thus, 
reductions in muscle quantity and quality are likely driven by CIDP-related neural 
factors, such as motor axon loss 10 and impaired neural signalling perhaps related to nerve 
lesions or segmental demyelination as reported in prior studies that presumably lead to 
accelerated muscle atrophy 4.  
Moreover, studies have shown proximal demyelination results in enlarged brachial and 
lumbar plexuses as well as enlargements in the cauda equina demonstrating segmental 
demyelination in nerves that have proximal roots. Findings from this study in 
combination with our previous results 10 indicate that both anterior and posterior leg 
compartments are affected to the same extent in CIDP. There does not seem to be any 
difference in muscle morphology specifically quantity and quality of skeletal muscle in 
the TA or within the constituent muscles of the triceps surae of patients with CIDP, and 
indeed muscles of the two major leg compartments seem to be equally affected. Thus, 
likely both the deep peroneal nerve as well as the tibial nerve has been affected to the 
same degree by the demyelinating process and subsequently the distal muscles have been 
compromised. This indicates that the insult to the nerve is more proximal possibly at its 
origin of the sciatic nerve and supports the finding of sacral plexus root enlargement 
reported previously 35.  
We were surprised by our initial findings in the TA muscle, which prompted us to 
explore whether another critical gait muscular group was affected by CIDP. In addition, 
the fiber type compositions of the main portions of the triceps surae are quite different 





gastrocnemeii with support from studies on age-related changes as outlined above. 
Furthermore, a major concern for patients with CIDP is ambulation, and quantifying how 
several key leg muscles involved in gait are affected by a chronic nerve demyelination is 
very pertinent to the well being and quality of life of those with CIDP. Our results are 
further supported by Ohyama et al (2017) who, using computed tomography, showed 
significant atrophy to be more pronounced in the distal musculature compared to 
proximal muscles of patients with CIDP 42. Thus, morphological alterations to distal 
skeletal muscle in patients seem to be uniform regardless of anatomical location or 
functional requirements. Furthermore, compositional changes within the muscle 
compartments, specifically infiltration by fat and connective tissue, may disrupt muscle 
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6 General Discussion and Summary  
6.1 General Discussion 
This thesis provides considerable unique experimental evidence concerning the 
consequences of chronic inflammatory demyelinating polyneuropathy (CIDP) on the 
human neuromuscular system. The first half of this thesis concentrated on the motor axon 
changes that accompany CIDP. The results in this body of work indicate that patients 
with CIDP have a loss of motor units, neuromuscular transmission instability, abnormal 
firing rates of individual motor units and neuromuscular conduction block (Chapters 2, 
3). The second half of this thesis focused on how these alterations to the motor axon and 
abnormal neuromuscular transmission behavior affect skeletal muscle mass and 
composition. The findings of the later chapters indicate that CIDP related motor unit loss, 
block and instability is associated with skeletal muscle atrophy as well as increased non-
contractile intramuscular tissue infiltration (Chapter 4). Furthermore Chapter 4 elucidates 
an important finding that patients with CIDP are weaker when normalized to fat-
corrected muscle volumes in the TA muscle of the anterior compartment that can be 
related to findings from the first two studies. This indicates there are intrinsic structural 
abnormalities within the contractile protein apparatus of the muscle fibers. The final 
Chapter (5) of this thesis investigates whether these distal symmetrical axonal losses and 
instability have homogeneous effects on the muscle tissue innervated. This was 
accomplished by using MRI to explore the portions of the triceps surae muscle group of 





of distal nerve loss and dysfunction, associated muscle undergoes uniform changes of 
atrophy and non-contractile tissue infiltration in all muscles regardless of functional 
differences or anatomical location. Combined, these findings provide a more 
comprehensive understanding of the current understanding of how CIDP affects the 
neuromuscular system as well mechanisms behind the functional limitations seen in 
patients with CIDP.  
Although not well understood, there is a consensus that CIDP related demyelination 
causes neuromuscular dysfunction, and it has been presumed that part of this dysfunction 
is due to neuromuscular conduction block and the loss of motor axons 1,2,3. However, 
studies to date have not quantified the losses of motor units or stability parameters 
associated with demyelinated motor axons in patients with CIDP. In this thesis, the 
results in Chapter 2 confirmed the suspected concept of motor unit loss by exhibiting 
reduced MUNEs in the tibialis anterior (TA) of patients with CIDP versus healthy control 
subjects. This finding is important as it confirms that chronic motor axon demyelination 
to proximal nerve roots and plexuses can impact motor unit number and function in a 
distal muscle 4. Chapter 2 also builds on this characterization by demonstrating increased 
neuromuscular jitter and jiggle in patients relative to controls, which reflects pathological 
alterations in neuromuscular action potential propagation or neuromuscular junction 
transmission instability. Importantly this Chapter demonstrates the utility of concentric 
needle derived DQEMG for the detection of motor unit loss and differences in 
neuromuscular transmission fidelity when comparing patients with CIDP to healthy 
controls. Furthermore, this Chapter highlights the significance of DQEMG as a valuable 





nerve conduction studies. Finally, the neuromuscular stability outcomes of Chapter 2 
indicate that jitter and jiggle are valuable indices for classifying axonal alterations in the 
early stages of disease, preceding the loss of motor units or the onset of muscle atrophy.  
Chapter 3 of this thesis builds upon previous findings of axonal transmission failure via 
single fiber motor unit experimentation 2. Numerous animal model studies using 
experimental autoimmune neuritis (CIDP equivalent in rodents) have demonstrated 
transmission disturbances in motor axons, neuromuscular junctions, and single muscle 
fibers, all of which culminate into failed action potential propagation in motor nerves or 
skeletal muscle fibers 5. Surprisingly, patients with CIDP demonstrated abnormally high 
firing rates of early recruited low-threshold motor units at low volitional contraction 
intensities. These high firing rates observed in small, early recruited motor units may 
reflect a compensatory strategy to mitigate the overall motor unit loss. Findings from 
Chapter 3 also indicate that CIDP related demyelination, blockage and axon loss might be 
more prominent in larger, later recruited motor units. The surviving smaller type I motor 
units must discharge at faster rates to produce the necessary force in the absence or 
blockage of faster later recruited type II motor units. The finding of conduction failure (in 
the form of diminished motor unit firing rates or complete block) supports the concept 
that transmission failure occurs in human patients with CIDP. Moreover, this 
susceptibility of motor units to demonstrate transmission failure and abnormal firing rates 
could have functional implications, specifically regarding quantity and quality of the 
muscle tissue innervated by unhealthy nerves. 
Indeed, MR imaging in the lumbar nerve roots and tibial nerve has shown nerve lesions 





severe distally, can be profound and likely has a direct significance on functional 
impairments.  However, very little data exist regarding the morphological characteristics 
of the limb musculature in patients with CIDP, specifically muscle quantity and quality. 
In Chapters 4 and 5 of this thesis, two MRI based techniques (T1 and T2 weighted scans) 
are utilized to reveal CIDP related quantitative and qualitative changes in skeletal 
musculature. Results of Chapter 4 indicated that compared to control subjects those with 
CIDP have structural alterations that ultimately affect the contractile capacity of muscle 
tissue. The most important findings from Chapter 4 are that patients with CIDP have 
lower total muscle protein quality and more non-contractile tissue infiltration in the TA, 
as indicated both by a greater amount of non-contractile tissue and elongated T2 
relaxation times, compared to healthy controls. This Chapter also demonstrates an 
interesting finding that patients with CIDP are weaker relative to volume of muscle even 
when compared using fat corrected muscle volumes normalized to force. This is 
significant because it indicates that patients with CIDP have disruptions to the intrinsic 
structural integrity at the molecular level of muscle proteins, supporting the concept that 
disruptions in neural innervation and function affect muscle protein quality. 
Consequently, these unfavorable changes to muscle tissue composition are likely key 
structural alterations that contribute to functional weakness in patients with CIDP. 
Chapter 5 investigates the homogeneity of the effects of chronic demyelination in a 
separate leg compartment Findings from Chapter 5 in combination with results from 
Chapter 4 indicate that both anterior and posterior leg compartments are affected to the 
same extent in CIDP. There does not appear to be any difference in muscle morphology 





muscles of the triceps surae in patients with CIDP. Findings from these two Chapters 
indicate that muscles of the two major leg compartments seem to be equally affected by 
the disease process.  Thus, likely both the deep peroneal nerve as well the tibial nerve 
have been affected to the same gradation by the demyelinating process and subsequently 
the distal muscles have been compromised. This indicates that the focal insult to 
peripheral nerves is more proximal possibly at their origin of the sciatic nerve and 
supports the findings of sacral plexus root enlargement that has been previously reported 
6,7. In summary, the studies presented have elucidated many neuromuscular deficits in 
patients with CIDP and this information may be essential in disease management as well 
in directing and assessing treatment modalities.  
6.2 Limitations  
The first half of this dissertation uses EMG techniques that are not without limitations. 
The characteristics of an EMG signal are largely affected by the level of voluntary 
contraction, the anatomical and physiological properties of the muscle, the physical 
characteristics of the electrode used to detect the signal as well as the position of this 
electrode relative to the active muscle fibres. A specific limitation related to MUNE 
consists of the challenge in maintaining concentric needle electrode positioning during 
intramuscular recordings. Although the DQEMG software provides visual feedback and 
cueing, inconsistent needle electrode positioning may affect the sizes of detected action 
potentials recorded from active motor units. Intramuscular concentric needle depth has 
also been shown to have a significant effect on MUNE calculation 8. Potential bias 
regarding depth and location of needle electrode intramuscular insertion was taken into 





detection of motor units was representative of the population of motor units within the 
muscle.  
There is clear evidence suggesting that that the level of force can have a significant 
impact on the sizes of both needle and surface detected motor unit action potentials 
sampled using DQEMG. The amplitude of the needle and surface detected motor unit 
action potentials increase as the level of force increases. Coupled with this change in 
action potential size is an increase in motor unit firing rate as well as a decrease in the 
magnitude of the MUNE values at higher force levels 9. In order for DQEMG to maintain 
its accuracy and usefulness, methods of controlling for the level of force must be efficient 
and applicable to the study design. In order to reduce force variability the studies in this 
body of work used a consistent measure of torque and root-mean square EMG during 
signal acquisition to provide an indication of the absolute or relative level of force or 
muscle activation. 
Motor unit number estimations and stability measures were conducted in the right leg 
(Chapters 2 and 3) and in the study calculating muscle quality and quantity the left leg 
(Chapter 4) was analyzed. This was done knowing that motor unit pathology is 
symmetrical in patients with CIDP 4.  This means that motor unit losses measured and 
detected in one side of the body should reflect losses in the opposite side to a similar 
degree. The left side was the non-dominate limb in 95% of all patients and controls tested 
and although not significant both plantar flexion and dorsiflexion strengths were slightly 
weaker in the non-dominate limbs of patients with CIDP. Additionally, the patient group 
studied throughout this thesis featured a more severe neuropathy, with a more extreme 








Loss of cells from the motor system occurs during the normal aging process, leading to 
reduction in the complement of motor neurons and muscle fibers. This latter age-related 
decrease in muscle mass is termed sarcopenia and is often exacerbated with the 
detrimental effects of a sedentary lifestyle in older adults, leading to a significant 
reduction in the overall reserve capacity of the neuromuscular system 13, 14, 15 16. The 
cellular processes that lead to age-related loss of spinal motor neurons in healthy adults 
are not well understood but it is widely agreed that nerve cell death is the precursor for 
the numerous neuromuscular adaptations seen with normal adult aging. These detrimental 
effects to the neuromuscular system manifest and are detectable by the six or seventh 
decade of life 17. The mean ages of the patients and control subjects in this thesis were 
approximately 60 years old. Therefore it is reasonable to expect that the majority of 
patients with CIDP would not only be expressing CIDP related neuronal changes but also 
age-related changes to neurons. Thus, it was important to have age-matched controls.  
This may affect the generalizability of the results found in this thesis. Patients with CIDP 
may be differentially affected as they age, compared to how CIDP may influence a group 
of disease free younger adults. 
Lastly, the patient and control experimental groups included a comparable number of 
males and females. The two groups were sex matched, however due to the rarity of the 
disease a sample size of 10-12 subjects was studied which did not provide enough 





6.3 Future Directions  
The studies contained within this thesis provide a foundation from which further 
investigation can build upon. To further elucidate, quantify and expand the findings of 
Chapter 2, with a study investigating the loss of motor units in a more proximal muscle 
would be of value. CIDP has demonstrated detrimental affects to distal human 
musculature, however it is not known whether similar demyelinating effects are expected 
in proximal muscles of the body.   Due to the length dependent nature of the disease it 
would be interesting to know if proximal muscles are preserved to a greater or lesser 
degree than distal muscles.  
Quantification of isotonic muscle power generation, force-velocity relationship and 
maximal contractile velocity might considerably complement the understanding of 
Chapters 3, 4 and 5 regarding how CIDP impacts muscle function.  Indeed, there is good 
evidence that voluntary isotonic (concentric and eccentric) contractions have different 
motor unit firing rates than voluntary isometric contractions 18,19. Therefore, 
intramuscular fine wire recordings could be collected during dynamic contractions in a 
distal muscle to assess the firing characteristics of individual motor units during a 
dynamic task. To complement Chapter 3 repetitive nerve stimulation at different 
frequencies could also be used to test for neuromuscular transmission failure in order to 
quantify whether and at what frequency demyelinated motor neurons fail to propagate 
action potentials. Knowing that patients with CIDP have abnormal motor unit firing rates 
and overall neuromuscular block it would be important to know at what specific 
frequency peripheral axons demonstrate this failure to provide verification for the 





 Furthermore, certain inferences made in Chapters 4 and 5 could have been further 
supported or enhanced with the inclusion of skeletal muscle biopsies. The incorporation 
of muscle biopsies could have supported the ideas in Chapter 3 of neuromuscular 
remodeling (fiber type grouping) in patients with CIDP. Muscle biopsies could also give 
a superior molecular understanding of muscle quality by evaluating single myofibril 
morphology 20. Nevertheless, the inclusion of muscle biopsies was not reasonable for 
these experiments as the majority of studies contained within this thesis concentrated on 
the dorsiflexor muscle groups, which are not considered suitable muscles to biopsy in 
comparison to muscles of the thigh for example. Obtaining and analyzing biopsies 
located in the quadriceps would provide insight for comparison with the TA, given the 
length-dependent nature of CIDP and the different fiber type proportions of these 
dissimilar muscle groups 21. In combination with the procedures mentioned above, it 
would be advantageous to include standard clinical measures of mobility or functional 
capacity, such as balance and coordination tests.  Moreover, subjective questionnaires 
that assess physical activity could offer evidence regarding the physical status of the 
subjects studied. The inclusion of these subjective measures may help delineate 
consequences of CIDP on the neuromuscular system.    
Finally, a longitudinal study of patients with CIDP, as well a more detailed outline of 
patient’s treatment regime could provide greater insight into the progression of CIDP 
related neuromuscular dysfunctions 20. Concurrent assessments of the motor system and 
the changes reflected by the different treatments (IVIG, PE and prednisone) offered to 
patients with CIDP would be helpful in determining how this autoimmune neuropathy is 





neuromuscular properties of patients with CIDP 22,23,24,25. Conceivably, a longitudinal 
study would also provide an opportunity to assess the effects of aging on CIDP. 
6.4 Summary and Significance  
Chronic Inflammatory Demyelinating Polyneuropathy causes numerous detrimental 
physiological and functional alterations to the human neuromuscular system. This 
dissertation comprises an amalgamated collection of novel and foundational experiments 
in patients with CIDP. Firstly, it provides concrete evidence for the chronic loss of 
demyelinated motor units that underlie muscle atrophy and weakness in patients with 
CIDP (Chapter 2). Secondly, this body of work demonstrates that in addition to the loss 
of motor units, patients with CIDP display severe instability in remaining motor units 
(Chapter 2). Furthermore, for the first time experimentally, I illustrate that patients with 
CIDP have abnormal motor unit firing rates across a broad range of contraction 
intensities. Indeed, shown in this thesis the chronic loss of motor units, the detectable 
instability and conduction block of action potentials seem to be associated with skeletal 
muscle atrophy as well the intramuscular infiltration of non-contractile tissue (Chapters 4 
and 5). Combined, the investigations contained within thesis provide a basis that will 
direct future experiments to further elucidate mechanisms that aid in the understanding of 
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of sarcopenia. Journal of Experimental Gerontology. (81): 28-36 
12. Xu S.X, Gilmore K.J, Szabo P, Zeppa J.J Baroja M.L, Haeryfar S.M.M, McCormick 
J.K. (2014). Superantigen-mediated CD11b+Ly6G+ neutrophil influx into the 
liver enhances abscess formation to promote Staphylococcus aureus survival in 






PUBLISHED JOURNAL REPLIES 
1. Kirk EA, Gilmore K.J, Rice C.L. (2018). An objective criterion for stimulation 
intensity may be necessary to properly assess muscle contractile properties. 
Journal of Neurophysiology. 6 (120): 3288 
2. Gilmore K.J, Morat T, Doherty T.J, Rice C.L. (2017). Reply to motor unit number 
estimations and neuromuscular fidelity in three stages of sarcopenia. Muscle and 
Nerve. 930-931 
PUBLISHED AND PRESENTED ABSTRACTS 
1. Gilmore K.J, Kimpinski K, Rice C.L (2019) Microscopic muscle architecture in 
chronic inflammatory demyelinating polyneuropathy. Canadian Society for 
Exercise Physiology (CSEP) Appl. Physiol. Nutr. Metab. 44(10): S75. (Oral 
presentation) 
2. Jacqueline Chevalier, Hao Yin, John-Michael Arpino, Caroline O'Neil, Zengxuan 
Nong, Kevin Gilmore, Jason Lee, Emma Prescott, Matthew Hewak, Charles L 
Rice, Luc Dubois, Adam H Power, Douglas W Hamilton, Geoffrey Pickering 
(2019) Microvascular stenosis in end-stage peripheral artery disease: role of 
partial endothelial to mesenchymal transition submitted Abstract to 2019 
Canadian Vascular and Lipid Summit. (Poster presentation) 
3. Chevalier J, Arpino J-M, Yin H, Prescott E, O’Neil C, Nong Z, Gilmore K.J, Lee J, 
Hewak M, Rice C.L, Dubois L, Power A, Hamilton D, Pickering G (2019) -
Microvascular stenosis in end-stage peripheral artery disease: role of partial 
endothelial to mesenchymal transition Arteriosclerosis, Thrombosis, and Vascular 
Biology; 39: A242 (Oral presentation)  
4. Fanous J, Gilmore K.J, Kimpinski K, Rice C.L (2018) An MRI investigating of the 
lower limb musculature in patients with chronic inflammatory demyelinating 





5. Kirk, E.A, Gilmore K.J, Rice, C.L  (2018) Motor unit firing rates during dynamic 
isokinetic fatiguing contractions in young and old men (Poster presentation) 
Appl. Physiol. Nutr. & Metab. 43: 10 (Suppl. 2): S69 
6. Kirk, E.A, Gilmore K.J, Doherty, T.J, Stashuk, D.W, Rice, C L (2018) Ageing. It’s a 
trap! Neuromuscular properties of the superior trapezius.  (Poster presentation) 
Proceedings of the XXii Congress of the International Society of 
Electrophysiology & Kinesiology (ISEK), PII.47, p.130  
7. Fanous J, Gilmore K.J, Kimpinski K, Rice C.L (2018) Investigating the triceps surae 
in chronic inflammatory demyelinating polyneuropathy patients using magnetic 
resonance imaging. Experimental Biology Annual Meeting (Poster presentation 
and award) The FASEB J.  vol. 32 no. 1 Supplement 641.2 
8. Gilmore K.J, Kirk E.A, Kimpinski K, Rice C.L (2017) Chronic inflammatory 
demyelinating polyneuropathy: weakness associated with reductions in motor unit 
discharge rates. Canadian Society for Exercise Physiology (CSEP) (Poster 
presentation) Appl. Physiol. Nutr. & Metab. 42: 10 (Suppl.): S76 
9. Gilmore K.J, Kirk E.A, Rice C.L (2017) Is there a cessation of motor unit remodeling 
as a compensatory strategy to age-related motor unit loss? American College of 
Sports Medicine (Poster presentation) Med. Sci. Sports and Ex. (Suppl 1. Vol. 
49, No. 5) p. 1031 
10. Gilmore K.J, Kimpinski K, Doherty T.J, Rice C.L (2016) Chronic inflammatory 
demyelinating polyneuropathy weakness is associated with reduced muscle mass 
and motor unit loss. Society for Neuroscience, (Poster presentation) Program 
No. 441.11/ ZZ3 Neuroscience Meeting Planner 
11. Gilmore K.J, Kimpinski K, Stashuk D.W, Doherty T.J, Rice C.L (2016) Chronic 
inflammatory demyelinating polyneuropathy: muscle atrophy associated with 
denervation and neuromuscular transmission instability. Experimental Biology 






12. Gilmore K.J, Doherty T.J, Kimpinski K, Stashuk D.W, Rice C.L (2015) 
Electrophysiological and neuromuscular properties of persons with chronic 
inflammatory demyelinating polyneuropathy (CIDP). CSEP Annual Meeting 
(Poster presentation & poster award) Appl. Physiol. Nutr. & Metab. 40: (9 
(Suppl. 1): S25 
13. Gilmore K.J, Allen M.D, Stashuk D.W, Rice C.L (2015) Neuromuscular 
transmission stability in very old world-class master’s athletes. 62nd ACSM 
Annual Meeting (Poster presentation) Med. Sci. Sport and Exercise. (Suppl 1. 
47, No. 5) p.864 
 
UNPUBLISHED PRESENTED ABSTARCTS 
1. Gilmore K.J, Kimpinski K, Rice C.L (2019) Microscopic muscle architecture in 
chronic inflammatory demyelinating polyneuropathy. Exercise Neuroscience 
Group Meeting Hamilton ON (Oral presentation) 
2. Gilmore K.J, Kimpinski K, Doherty T.J, Rice C.L (2018) The effects of 
demyelination in chronic inflammatory demyelinating polyneuropathy (CIDP) on 
neuromuscular properties, muscle quantity and quality. First International Motor 
Impairment meeting Sydney Australia (Oral presentation)  
3. Gilmore K.J, Kirk E.A, Kimpinski K, Doherty T.J, Rice C.L (2018) Alterations in 
motor unit firing rates in patients with chronic inflammatory demyelinating 
polyneuropathy. International Motorneuron Society (IMS) Boulder Colorado 
(Poster presentation) 
4. Gilmore K.J, Kimpinski K, Stashuk D.W, Doherty T.J, Rice C.L (2015) chronic 
inflammatory demyelinating polyneuropathy: muscle atrophy associated with 
denervation and neuromuscular transmission instability. London Health Research 





5. Gilmore K.J, Doherty T.J, Kimpinski K, Stashuk D.W, Rice C.L (2015) 
Electrophysiological and neuromuscular properties of persons with chronic 
inflammatory demyelinating polyneuropathy (CIDP). Exercise Neuroscience 
group meeting Guelph ON (Oral Presentation)  
6. Xu S.X, Gilmore K.J, Szabo P, Baroja M.L, Haeryfar S.M, McCormick J.K (2012) 
Superantigens promote abscess formation and bacterial survival in the liver during 
Staphylococcus aureus sepsis. London Health Research Day (Poster 
Presentation/Oral Presentation)  
7. Gilmore K.J, McCormick J.K. (2013) Polarizing invariant natural killer T cells 
towards a Th2 phenotype reduces disease severity in intra-abdominal sepsis. The 
American College of Surgeons Clinical Congress, Washington, D.C. (Poster 
presentation) 
8. Anantha RV, Mazzuca D, Xu S.X, Gilmore K.J, Shrum B, Mele T, Fraser D, Martin 
C, Haeryfar S.M, McCormick J.K. (2013) Polarizing invariant natural killer T 
cells towards a Th2 phenotype reduces disease severity in intra-abdominal sepsis. 
The Canadian Surgical Forum, Ottawa, ON (Oral presentation) 
9. Anantha R.V, Mazzuca D, Xu S.X, Gilmore K.J, Shrum B, Mele T, Fraser D, Martin 
C, Haeryfar S.M, McCormick J.K. (2013) Th2-polarized invariant natural killer T 
cells reduce disease severity in intra-abdominal sepsis. Clinician Investigator 
Trainee Association of Canada/Canadian Society for Clinical Investigation 
Annual Meeting, Ottawa, ON (Second Place Winner). (Poster presentation) 
10. Anantha R.V, Mazzuca D, Xu S.X, Gilmore K.J, Shrum B, Mele T, Fraser D, C 
Martin C, Haeryfar S.M, McCormick J.K. (2013) Polarizing invariant natural 
killer T cells towards a Th2 phenotype reduces disease severity in intra-abdominal 
sepsis. Clinician Investigator Training Association of Canada Young Investigators 
Forum, Ottawa, ON (Oral presentation)     
11. Anantha R.V, Mazzuca D, Xu S.X, Gilmore K.J, Shrum B, Mele T, Fraser D, Martin 





cells towards a Th2 phenotype reduces disease severity in intra-abdominal sepsis. 
The Annual Robert Zhong Department of Surgery Research Day, London, ON 
(Poster presentation) 
12. Anantha R.V, Mazzuca D, Xu S.X, Gilmore K.J, Shrum B, Mele T, Fraser D, Martin 
C, Haeryfar S.M, McCormick J.K. (2013) Polarizing invariant natural killer T 
cells towards a Th2 phenotype reduces disease severity in intra-abdominal sepsis. 
General Surgery Residents Research Day, Division of General Surgery, London, 
ON. (Oral presentation) 
13. Xu S.X, Gilmore K.J, Baroja M.L, Summers K, Haeryfar S.M, McCormick J.K. 
(2013) ‘Superantigen-mediated immune suppression in the liver during 
Staphylococcus aureus sepsis’ 8th Annual Infection and Immunity Research Form 
London, ON, Canada, (Oral presentation) 
14. Xu S.X, Gilmore K.J, Baroja M.L, Summers K, Haeryfar S.M, McCormick J.K. 
(2013) ‘Superantigen-mediated immune suppression in the liver during 
Staphylococcus aureus sepsis’ Staphylococcal Disease Gordon Research 
Conference (Poster presentation) 
15. Xu S.X, Gilmore K.J, Baroja M.L, Summers K, Haeryfar S.M, McCormick J.K. 
(2013) ‘Superantigen-mediated immune suppression in the liver during 
Staphylococcus aureus sepsis’ 26th Annual Canadian Student Health Research 
Form (Poster presentation) 
INVITED SEMINARS AND LECTURES  
Memorial University - Invited seminar speaker: Biomedical Sciences division in the 
Faculty of Medicine St. Johns Newfoundland (March 24th, 2019) 
Western University - Guest lecturer in an undergraduate class Anatomy and Cell Biology 
ACB 2221(Oct 18th, 2018)  
Los Angeles Biomedical Research Institute - Invited seminar speaker: Divisional 
Research Group at Harbor- UCLA Medical Center: Motor Unit Number Estimations In 





Invited - Motor Impairment blog posting lead author 
https://motorimpairment.neura.edu.au 
Laurier University - Invited guest lecturer for a graduate course: Selected topics in 
Neuromechanics of Human Movement (KP 697) 12 July 2017 Decomposition based 
Quantitative Electromyography (DQEMG) (MSc/PhD) workshop  
Western University - Mentored a visiting Master’s student to learn a neuromuscular 
technique (Decomposition based Quantitative Electromyography) (DQEMG) (Sept-Oct, 
2016) 
Western University - Guest Lecturer: undergrad/graduate Neuromuscular Physiology 




Accessibility at Western (AODA)      09/12/2019 
Supervisor Health and Safety Awareness      09/12/2019 
Comprehensive WHMIS        09/12/2019 
Laboratory-Environmental Waste Management Safety Training  09/12/2018 
Biosafety Training        09/12/2018 
Safe Campus Community        09/12/2016  
Certified Phlebotomist        08/17/2016 
Community First Aid        04/30/2014 
Basic CPR-Red Cross        06/22/2014  
ACVS Animal care and use 
Basic Rodent Handling 
Basic Mouse or Rat Workshop 
Mouse or Rat Anesthesia 
Gas Anesthesia 
Blood Collection Techniques in Mouse or Rat 
Techniques in Mouse or Rat 
Recovery Mouse or Rat Surgery Room Methodology I and II 
Surgical Pack Preparation 
Microtome training (tissue prep and sectioning) 
Light Microscope training (Fluorescent Light Microscopy) 
Cryostat Training (tissue prep and sectioning) 
Monitoring Assessment and Intervention 
VOLUNTEEER EXPERIENCE  





Let’s Talk Science instructor (grades 4 and 5) 2013 
Student Volunteer at University Hospital, Victoria Hospital, Parkwood Hospital (London 
ON) and Strathroy Middlesex General Hospital (Strathroy ON) 2010-2014 
Addictions Treatment Center OATC (London ON) 2010-2012 
REASERCH Related WORK EXPERIENCE 
Teaching Assistant- Anatomy and Cell Biology 2nd year gross cadaveric anatomy: 
Conducted weekly laboratory sessions in gross anatomical dissection, 2018 
 
Teaching Assistant- Health Science 2nd year gross anatomy: Conducted weekly 
laboratory sessions in anatatorium, 2014-2015 
 
Junior Research Histologist- Company Sernova Inc. (Supervisor: Delfina Siroen)  
Research Project: Cell pouch histological examinations. Phase III clinical study in 
subjects with diabetes; 2013-2014 
 
Work-Study Student (Supervisor: Dr. John K. McCormick) 
Research Project: Superantigen-mediated immune suppression in the liver during 
Staphylococcus aureus sepsis’. 2011-2013 
 
Junior Research assistant- Company Sernova Inc. (Supervisor: Delfina Siroen)  
Research Project: Cell pouch histological examinations. Phase I/II clinical study in 
subjects with diabetes; measuring of safety and efficacy. 2010-2012 
 
Work-Study Student (Supervisor: Dr. John K. McCormick)  
Research project: Staphylococcal superantigens in colonization and disease. 2010-2011 
 
Summer Student (Supervisor: Dr. John K. McCormick) 
Research project: Staphylococcal superantigens in colonization and disease. 2009-2010 
 
 
  
